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Does Patient Dementia Limit the Use of Cardiac Catheterization in  
ST-Elevated Myocardial Infarction? 
 
Marianne Chanti-Ketterl 
 
ABSTRACT 
 
Regardless of age or mental capacity, percutaneous coronary intervention 
(PCI) is the first line of treatment for ST-elevated myocardial infarction 
(STEMI).  This study evaluates the disparities in the use of diagnostic cardiac 
catheterization and PCI in STEMI patients with dementia. A retrospective 
analysis was performed of Florida‟s comprehensive inpatient surveillance 
system for the years 2006-2007 with admission diagnosis of STEMI. Logistic 
regression analysis was used to identify disparities in the use of intervention 
among all STEMI patients. A total of 8,331 STEMI patients met the inclusion 
criteria. Of these, 77% were catheterized and of these 67% received PCI. A 
total of 605 (7.3%) were demented. Patients with dementia were less likely 
to be catheterized (RR 0.4, 95% CI 0.3-0.5) and less likely to receive PCI 
within 24 hours (RR 0.5, 95% CI 0.4-0.6). This study concludes that STEMI 
patients with dementia were much less likely to receive cardiovascular 
interventions.  
  
1 
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
 
According to the American Heart Association (AHA), an American will suffer 
some form of coronary event every 25 seconds. The annual incidence of 
myocardial infarctions (MI) in the United States for 2009 is projected to be 
610,000 new attacks and 325,000 recurrent ones(3). The AHA Get With the 
Guidelines estimates that about 32% of these MIs are ST-Elevated 
Myocardial Infarctions (STEMIs)(3); about one third of these will result in 
death within 24 hours of the onset of symptoms(4). 
 
Although the trend in the number of people afflicted by myocardial infarction 
has steadily decreased in recent years, due in part to advancements in 
technology and treatment such as the use of Percutaneous Coronary 
Intervention (PCI), the disparities in care for certain groups have not 
improved. Studies still report that minorities, the elderly, and women with 
heart disease are undertreated, less likely to receive PCI, and are more likely 
to die during hospitalization(3, 5-7). 
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The aging of the population and the rising number of seniors suffering from 
chronic degenerative diseases have major impacts on public health. The 
Centers for Disease Control and Prevention estimate that 80% of older 
Americans are living today with at least one chronic illness(6). One such 
growing problem is dementia; a syndrome characterized by progressive 
mental deterioration.  
 
The World Alzheimer Report conducted a systematic review of 147 studies 
globally and estimated that in the year 2010, 35.6 million people will suffer 
from dementia worldwide(8). An earlier estimate by Plassman et al. from the 
Aging, Demographics, and Memory Study (ADAMS) sample, a subcohort from 
the Health and Retirement Study (HRS) of 856 individuals 70 years or older 
from different regions in the United States, estimated the prevalence of 
dementia among people older than 71 at 13.9% which translates to about 
3.4 million people in the United States in 2002 and approximately 9.7% 
prevalence for Alzheimer‟s type dementia for those over 71 years of age for 
that year(9). However, a report published in 2009 by the Alzheimer‟s 
Association suggests that 5.3 million Americans have Alzheimer‟s dementia 
(AD)(10). Studies show that the prevalence of dementia doubles with every 
5-year increase after 65 years of age(6, 8, 11). According to the Alzheimer‟s 
Association report for 2009, from the year 2000 to 2006 the death 
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percentage attributable to Alzheimer‟s disease increased 46.1% in contrast to 
heart disease, which decreased 11.1%(12). 
The health cost of dementia is profound; it not only affects the patient but 
the entire family and society as well. The economic worldwide expenditure 
for dementia is $315 billion(8). In 2005, the direct cost to Medicare and 
Medicaid for Alzheimer‟s disease alone escalated to $148 billion in the United 
States(10). The estimated total cost of cardiovascular disease for 2009 was 
$475.3 billion dollars(3); it seems evident that this is a public health crisis. 
Consequently it is imperative to recognize the impact of these two diseases 
combined and acknowledge the health and socio-economic cost to future 
generations.  
 
1.1 Main Aim of the Study 
The magnitude of this problem is noteworthy, the increased risk of disability 
from the combination of dementia and heart disease is large, and the health 
care costs associated with both pathologies are worrisome for this and future 
generations. This alarming health care problem prompted me to perform a 
retrospective cohort analysis of the inpatient surveillance data from Florida to 
determine if there is disparity in the use of diagnostic cardiac catheterization 
for ST-Myocardial Infarction patients with a diagnosis of dementia versus 
patients without a diagnosis of dementia after controlling for the following 
patient and hospital factors: age; gender; ethnicity; zip code SES; year of 
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hospital admission; hour of arrival at the emergency department; source of 
admission; principal payer and the following comorbidities: hypertension 
(HTN), diabetes mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP), 
obesity, smoking history (SMK), depression (DEP), end stage renal disease 
(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF), 
chronic obstructive pulmonary disease (COPD) and alcohol abuse (OH). 
 
1.2 Secondary Aims of the Study 
1. To determine if there is a difference in PCI use between STEMI patients 
with and without dementia who underwent cardiac catheterization after 
controlling for the following patient and hospital factors: age; gender; 
ethnicity; zip code SES; year of hospital admission; hour of arrival at the 
emergency department; source of admission; principal payer and the 
following comorbidities: hypertension (HTN), diabetes mellitus type 2 
(DM), stroke (STRK), hyperlipidemia (HLP), obesity, smoking history 
(SMK), depression (DEP), end stage renal disease (ESRD), chronic kidney 
disease (CKD), congestive heart failure (CHF), chronic obstructive 
pulmonary disease (COPD) and alcohol abuse(OH). 
 
2. To ascertain if there is a disparity of CABG use between STEMI patients 
with and without dementia who underwent cardiac catheterization after 
controlling for the following patient and hospital factors: age; gender; 
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ethnicity; zip code SES; year of hospital admission; hour of arrival at the 
emergency department; source of admission; principal payer and the 
following comorbidities: hypertension (HTN), diabetes mellitus type 2 
(DM), stroke (STRK), hyperlipidemia (HLP), obesity, smoking history 
(SMK), depression (DEP), end stage renal disease (ESRD), chronic kidney 
disease (CKD), congestive heart failure (CHF), chronic obstructive 
pulmonary disease (COPD) and chronic alcohol abuse (OH). 
 
3. To determine if there is a difference between the days to procedure (PCI 
or CABG) for STEMI patients with and without dementia after controlling 
for the following patient and hospital factors: age; gender; ethnicity; zip 
code SES; year of hospital admission; hour of arrival at the emergency 
department; source of admission; principal payer and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH).  
 
4. To identify if having dementia affects the length of hospital stay for STEMI 
patients after controlling for the following patient and hospital factors: 
age; gender; ethnicity; zip code SES; year of hospital admission; hour of 
arrival at the emergency department; source of admission; principal 
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payer and the following comorbidities: hypertension (HTN), diabetes 
mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP), obesity, 
smoking history (SMK), depression (DEP), end stage renal disease 
(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF), 
chronic obstructive pulmonary disease (COPD) and chronic alcohol abuse 
(OH). 
 
Other factors that will be considered in the analyses include, hospital PCI 
volume, in-hospital mortality, day of the week admitted, socio-economic 
status, and any additional procedures that were performed during the 
hospital stay. 
 
This study was approved and exempted by the Institutional Review Board of 
the University of South Florida on March 19th, 2010. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Descriptive Epidemiology of Dementia 
Dementia is a chronic syndrome caused by a variety of pathologies and 
conditions that involve the loss of mental capacity, with emphasis in memory 
loss, severe enough to interfere with activities of daily living (10, 13, 14). It 
includes memory, learning, orientation, language, comprehension and 
judgment deterioration (8, 13, 14). When mild problems in these areas are 
observed that do not interfere with daily life, the syndrome is referred to as 
Mild Cognitive Impairment (MCI)(10). Some cases of MCI develop into 
dementia and others do not; the reason for this is still not clear. 
 
Recent studies approximate the prevalence of dementia in the United States 
at about 13%(9, 10, 12). Studies also confirmed that this prevalence doubles 
with every 5-year increase in age after age 65 (6, 8, 11, 13). The most 
frequent type of dementia accounting for 80% of cases is Alzheimer‟s disease 
(AD) with approximately 5.3 million Americans affected in 2010(12).  The 
Alzheimer‟s Association estimates that there‟s a new case of Alzheimer‟s in 
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the United States every 70 seconds(10) and that by the year 2050 this 
estimate will have decreased to every 33 seconds(12). 
 
Data from the CDC(15), reported the annual crude death rate of AD at 24.2 
per 100,000 population in 2006, the same figure as diabetes mellitus. The 
age-adjusted death rate for AD that year was 22.6 per 100,000 U.S. 
standard population(15), a decrease of 1.3% from 2005 to 2006, making it 
the seventh leading cause of death in the United States in 2006(15, 16).  
According to Heron et al., in 2006 there were 72,432 deaths caused by 
Alzheimer‟s disease, which constituted 3% of the total deaths in the United 
States(15, 16). However underreporting AD on death certificates as cause of 
death has been well documented, and more recent estimates suggest that 
AD is the fifth leading cause of death in Americans aged 65 and older(10). 
 
A meta-analysis study conducted by Alzheimer‟s Disease International 
estimates that the prevalence of dementia in North America will increase 63 
percent over the next twenty years, mainly due to the demographic shift. 
Current estimates indicate that there are currently 35.6(8) million people 
worldwide with this syndrome and of these 5.3(10) million with Alzheimer‟s 
dementia in the United States, of which 5.1(10) million are over the age of 
65. Two hundred thousand people younger than 65 have what scientists call 
early onset Alzheimer‟s(10) and the rest are late onset dementia. 
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2.1.1 Pathology of Alzheimer Type Dementia 
Even though it is known that the underlying cause of most dementias, 
including AD is genetic, the exact mechanisms are still unknown. Dementia is 
now known to be the result of a combination of pathological disruptions in 
the brain that end up injuring brain cells, making them loose their functional 
capacity. Most scientists agree that the pathology of AD may have multiple 
causes, with some factors yet to be discovered. Among the most commonly 
understood pathological risk factors to date are genetic, inflammation, 
oxidative stress, hormonal changes and head injury(17, 18). 
 
Established characteristics of the Alzheimer‟s brain as observed in 
pathological studies are amyloid (neuritic) plaques, neurofibrillary tangles 
and loss of connection between the cells which lead to cell death(13, 17, 19-
21). Neuritic plaques are composed mainly of deposits of beta-amyloid 
protein, which can lead to increased microglia and reactive astrocytes(21); 
while neurofibrillary tangles, or intraneuronal bundles, are composed mainly 
of a protein called tau, which causes a disruption in the neuron‟s transport 
system leading it to fail(13). 
 
Few epidemiological studies have focused on the neuropathology of 
dementia(21, 22). A recent study by Matthews et al.(21) demonstrated that 
  
10 
 
neocortical pleuritic plaques accounted for 8% of the attributable risk at 
death for dementia and 11% neurofibrillary tangles(21). However although 
dementia severity seems to correlate better with the tangles than the 
plaques(17, 23), it has to be noted that tangles are not specific of AD (18), 
these can be seen in many other pathologies. 
 
2.1.2 Risk Factors for AD 
Epidemiological studies have demonstrated that AD may be caused by 
multiple factors; some from early life exposures (18, 24) and others from 
risk factors present later in life (18, 25-27). Figure 2-1 shows a summary of 
the risk factors known to be linked to Alzheimer‟s disease. The middle 
column shows how these risk factors are associated with brain reserve(28) 
and how they modify the clinical expression of dementia/AD. 
 
2.1.2.1 Age 
The main risk factor for dementia is age (6, 8, 9, 18, 21, 29, 30) and it is 
also the main contributor to the attributable risk at death (18% AR)(21). The 
Centers for Disease Control and Prevention (CDC) estimate that by the year 
2030, one in five Americans will be over 65 years old (6). Consequently as 
the population experiences demographic ageing, the prevalence of dementia 
increases. 
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Figure 2-1. Risk Factors for Dementia type Alzheimer’s. Table modified from 
Borenstein AR. [Unpublished Lecture Notes on Analysis and Presentation of 
Results].  Class: Practical Issues in Epidemiology, Summer Semester 2010. 
University of South Florida; 2010. Accessed with permission, 8/20/2010(1, 
2). 
 
The state of Florida has one of the largest elderly populations in the country. 
In 2006 and 2007 Florida‟s general population was 18,089,888(31) and 
18,251,243(32) respectively. Of these in 2006 there were 3,037,704(33) 
adults sixty five years and over, and in 2007 there were 60,660 more seniors 
over 65 than the previous year(34). In 2009 the population over 65 years of 
age in Florida totaled 3,195,841(35) an increase of 158,137 seniors in 3 
years. Based on the U.S. Census Bureau statistics, it is estimated that 
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Florida‟s elderly population will surpass the 7.7 million(36), or 27.1%(37) by 
the year 2030. 
 
2.1.2.2 Genetics 
The Alzheimer‟s Association noted in their 2009 report that clearly familial AD 
is seen in fewer than  5% of cases(10). Several studies in twins have 
confirmed that heritability plays a major role at any age(26, 38). In those 
over the age of 70 heritability or the proportion of disease explained by 
genetic inheritance is remarkably high at 79% (38). Heritability does not 
differ in gender after controlling for age(38). 
 
One of the most studied genes involved with AD is apolipoprotein E. This 
gene is involved in the transport of cholesterol in the blood. There are 
several forms or alleles of the gene, allele e4 is the one that has been found 
to influence the development of dementia. Recent research confirms that 
although everyone who inherits one APOE-e4 gene is at high risk, those who 
inherit two genes are at even higher risk(10, 13). However just like all 
multifactorial conditions, carrying the gene does not guarantee that a person 
will inherit AD. A recent study found that APOE-e4 has a stronger effect on 
women than men but the attributable risk due to APOE-ε4 decreases with 
increasing age(26). 
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When Alzheimer‟s disease occurs in people in their 40‟s and 50‟s it is refer to 
as “early-onset” Alzheimer‟s disease. However, over 90% of Alzheimer‟s 
disease occurs in people older than 60 years old, which is referred to as 
“late-onset” AD(13). The early onset form of the disease seems to be linked 
to a chromosome 14 (14q24.3), while the late onset and sporadic cases of 
AD has been linked to apolipoprotein ε(APOE) on chromosome 19(17). 
 
2.1.2.3 Gender and Hormones 
Although some recent studies show no gender difference in the overall 
incidence risk of developing dementia(9, 39), some say there is(10, 25). 
Studies where prevalence has been measured show consistently higher rates 
for women than for men, but this could be explained by longer life spans of 
the former. Some studies propose that postmenopausal women taking 
hormone replacement therapy have greater risk of developing dementia type 
Alzheimer‟s compared to those who do not take hormone replacement 
therapy(29). Women who are APOE-e4 carriers are at greater risk of 
developing AD than men(26). 
 
Much research in men and women has focused on the role of hormones, 
estrogen in particular, and the timing of the onset of Alzheimer‟s disease. 
Basic scientists have demonstrated the benefits of estrogen on cognition(2); 
however a clear association between the use of estrogens and Alzheimer‟s 
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disease in humans has been obscured by poorly design studies(2, 17, 40) 
yielding inconclusive results due to many factors such as the use of different 
estrogen formulations, patterns and methods used to measure the 
biomarker(40). Although controversial, most of these studies conclude that 
further research is needed with younger volunteers willing to be followed for 
longer periods of time. 
 
2.1.2.4 Education & Socioeconomic Status (SES) 
Epidemiological studies have shown that low education is a risk factor for AD 
and that higher socioeconomic status delays the onset of the disease (10, 13, 
17, 24-28). This effect may be modified and/or confounded by many other 
early-life developmental factors, such as parental education, occupation, 
poor nutrition, and other deprivations in childhood(24) which may lead to 
lower brain volume, lower IQ and consequently lower educational 
achievement(28). One of the main contributors to AR [attributable risk] at 
death for dementia was small brain (12%)(21). 
 
These observations are consistent with the “threshold” theory of brain 
reserve(24, 28). Mortimer proposed that in order to see the clinical 
expression of AD two conditions must be met: first, propensity to form the 
pathognomonic AD lesions in the brain and second second, reaching a critical 
functional brain volume in which normal cognitive function cannot be 
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sustained (28). Although (28).  Although it may be possible to reverse the 
accumulation of AD pathology because of its strong dependence on inherited 
genes, controlling for cardiovascular comorbidities may hinder the 
progression of brain loss through preservation of functional brain tissue. 
 
2.1.2.5 Cardiovascular Risk Factors & Cognition 
Well known risk factors for dementia include hypertension, hyperlipidemia, 
and type 2 diabetes mellitus(28, 30, 41). The atherosclerotic process is a 
common link between cardiovascular disease and dementia. Controversy 
remains as to whether pharmacological treatment for cardiovascular disease, 
such as statin therapy, has the ability to reduce the incidence of dementia.  
Some studies have not found an association between statin use and AD(42, 
43) while others have(44, 45); however many questions remain. Different 
studies have studied different types of statins and this may explain some of 
the differences in the findings. Statins can be lipophilic (simvastatin, 
atorvastatin, cervastatin) or hydrophilic (pravastatin, fluvastatin, 
rosuvastatin)(46). Different study designs, cross-sectional vs. prospective, 
have been used in different populations; therefore results cannot be easily 
compared. The findings suggest that cross-sectional analyses are likely to 
find an inverse relationship between statin use and dementia, but that 
prospective do not(47). Some prospective studies have not seen significant 
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differences in incidence(43); this may be due in part to the different study 
designs, indication bias and/or confounding(48). 
 
Haag et al. (46) studied the different types of statins in relation to AD in a 
prospective study using the population-based Rotterdam Study and 
surprisingly found that effect sizes were similar for both lipophilic and 
hydrophilic statins; there was no dose-response relationship and a protective 
effect was observed regardless of treatment duration(46). 
 
Overall the literature is inconclusive about preventive treatment with statins 
for Alzheimer‟s disease or cognitive functional improvement. More research is 
needed with a standardized approach to come to any valid conclusions. 
 
2.1.2.6 Environmental Factors & Physical Activity  
Some environmental protective and risk factors for AD, occur early in life. 
Borenstein et al. (2006) reviewed the early-life risk factors that may 
influence the development of AD and found that Down Syndrome and trauma 
to the head has been closely associated with AD in several studies; birth 
weight and sibship size were inversely related to the development of AD; and 
the protective effect of learning multiple languages during childhood had 
inconclusive results and required further studies(24). 
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Recent studies are looking closer at the effect of diet in the prevention or 
delay of AD. Based on the same cardiovascular benefits, diets rich in 
antioxidants, low-saturated fats, and high unsaturated fats also seem to be 
protective of dementia (25, 49-51). Some studies indicate that polyphenols, 
such as polyphenolic flavanoids found in grapes, apples and wine have 
neuroprotective properties that slow down the beta-amyloid deposition via 
oxidative stress resistance (49, 50), and reduction in toxin-build up and 
chronic inflammation(52). 
 
Other environmental factors such as smoking have been known to increase 
the risk of AD (53-56). Some studies have reported benefits of smoking at 
older age but this may reflect selection bias(57). 
 
Physical activity is known to improve cardiovascular health and thus many 
studies have linked it to better outcomes on patient cognition(58), risk and 
progression of dementia(25, 59, 60). Depression has been linked with both 
cardiovascular disease and dementia(30, 34, 41, 61, 62) as well. It is 
considered a prodromal manifestation of dementia(63) and has been 
associated to a two-fold increase risk for dementia(34); recent studies found 
that this association is not explained by vascular risk factors(64). 
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2.2 Treatment for Dementia 
Unfortunately the majority of dementias are irreversible and do not respond 
well to treatment. A few types of dementia are reversible, such as those 
caused by hormone or vitamin imbalances, depression, and/or drugs, 
including alcohol.  
 
There are several treatments available to try to slow down the progression of 
AD and control some of the symptoms. Antioxidants; cholinesterase 
inhibitors such as Donepezil (Aricept®), Rivastigmine 
(Excelon®),Galantamine (Razadyne®), and Cognex®; memantine 
(Namenda®) which is a glutamate inhibitor; and antipsychotics or 
neuroleptics that can help control behavior in later stages of AD. 
Antipsychotics or neuroleptics, antidepressants and anxiolytics may be 
needed to control some of the symptomatology.  
 
 
2.3 Cardiovascular Epidemiology – STEMI 
2.3.1 Statistics for 2009 
According to the American Heart Association Heart Disease & Stroke 
Statistics 2009 Update, the prevalence of cardiovascular disease (CVD) in the 
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United States for 2006 was 36.3% (80.0 Million people), which is one in 
every three adult Americans. Over 38 million of these, or a prevalence of 
47.6%, were over the age of 60(3).  
 
The number of myocardial infarctions in the United States in both men and 
women in 2006 was 7,900,000 (9.87% of all cardiovascular diseases). Of 
these, about 29% were STEMIs(3). In 2006, 55% of seniors 65 and over had 
a first listed diagnosis of CHD in short stay hospitals(3). In people 40-59 
years old, the prevalence of cardiovascular disease was roughly 38% and it 
almost doubled for the age group 60-79 to 73%(3). Given the increase in the 
prevalence and incidence of dementia and coronary heart disease with age, 
their combined occurrence increases more than exponentially. 
 
In the last several decades the mortality rate from myocardial infarctions has 
decreased gradually, thanks in part to better treatment. However, the 
prevalence remains at 3.6% for the year 2006(3). 
 
Acute coronary syndromes, STEMI in particular, have been a significant 
public health problem in developed nations for many years. The American 
Heart Association estimates that about half a million STEMI events occur in 
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the United States per year and one third of the patients with these will die 
within 24 hours of the onset of ischemia(4, 5).  
 
In the ten year span from 1996 to 2006 the number of cardiac 
catheterizations decreased by 46,000 annually(3). Statistics confirm that 1.3 
million PCIs, previously refered to as percutaneous transluminal coronary 
angioplasty (or PTCA), were performed in the United States in 2006 alone 
and approximately 50% of these were carried out in people over 65 years of 
age.(3)  
 
Although the morbidity as well as the mortality of heart disease has declined 
in the last decades, the use of PCI has increased. Statistics show a 30% 
increase in PCI procedures from 1996 to 2006(3) associated with a 
staggering economic cost(65). In 2006 the average fee of a PCI procedure 
per patient was $48,399(3). It is estimated that the direct and indirect total 
cost of cardiovascular disease in the United States for 2009 reached $475.3 
billion(3). 
 
Despite global treatment improvement in cardiovascular diseases, differences 
in interventions are still evident and the allocation of PCI is no different. 
Minorities, women, the elderly and those with low socioeconomic conditions 
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are still undertreated(4, 7, 66, 67). Some scientists argue that the overall 
outcome of STEMI patients, despite known disparities, is not yet optimal(5). 
This may be in part due to a lack of translation from bench to practice 
amongst clinicians. To decrease this gap in knowledge and treatment, the 
American College of Cardiology (ACC) and the American Heart Association 
have teamed up to produce reports with the latest scientific evidence, 
provide guidelines for clinicians to follow when treating STEMI patients(68) 
and supply algorithms and tables to help with critical management decisions.  
 
2.3.2 STEMI 
In order to understand the treatment for STEMI, it is necessary to review the 
basic pathophysiology of this condition.  STEMI is a type of transmural acute 
ischemia that is typically recognized early in the electrocardiogram (ECG) by 
an elevation of the ST segment; the more ST segments that are elevated, 
the more extensive the injury. The location of the ischemia can be 
documented by the altered leads on the ECG. The diagnosis of STEMI is also 
supported by the presence of ascending cardiac enzymes, specifically 
troponin. The usual cause of a STEMI is a compromise in the blood flow to 
the myocardium, due most frequently to a rupture of an atherosclerotic 
plaque; but it can also be caused by other mechanical or dynamic 
obstructions (vessel spasm) as well as inflammatory mechanisms(4).  
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2.3.3 Treatment Guidelines for STEMI and PCI 
Treatment for STEMI patients should be based on the recommendations 
provided in the guidelines for the management of patients with ST-elevated 
myocardial infarctions from the American College of Cardiology Foundation 
(ACC) and the American Heart Association Task Force on Practice Guidelines 
(AHA)(4, 5, 68, 69). The latest update was provided the last quarter of 2009.  
 
2.3.4 Preventive Treatment 
According to the 10-year risk based on the Framingham equation, amongst 
the elderly, comorbid conditions such as established coronary heart disease, 
hypertension, hypercholesterolemia, diabetes and peripheral vascular disease 
increase the risk of STEMI by over 20%(4).  The ACC/AHA recommends 
quitting smoking and maintaining a low fat diet rich in fruits, vegetables, 
whole grains and soluble fibers. Maintaining an ideal weight and an active 
lifestyle is vital for preventing cardiovascular events and adverse outcomes 
after the onset of the disease(3). Recommendations for the proper treatment 
of hypertension are emphasized in the elderly, since many research studies 
indicate that systolic hypertension is predictive of adverse outcomes in this 
population, and should be treated even with normal diastolic blood 
pressure(4).  
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2.3.5 Recommendations for Transportation of STEMI Patients 
Modified recommendations from the ACC/AHA now encourage patients with 
symptoms suggestive of STEMI to call the emergency medical services (EMS) 
and seek medical treatment as soon as symptoms begin(4). Several studies 
have confirmed the association between the mode of transportation to the 
hospital and early reperfusion therapy(5, 68, 69). Better prognosis is 
expected for those patients who arrive promptly after the onset of symptoms 
to a PCI-capable facility or who are transferred within 4 hours of arriving to a 
non-PCI-capable facility to a facility that can perform PCI(68). See Appendix 
1. 
 
A study by Canto JG, Zalenski RJ, Ornato JP, et al (2002) estimated that 
76% of the patients choose alternative modes of transportation to the 
emergency department instead of using EMS(4). Other studies indicate 
longer waiting times if the patient does not arrive to the emergency 
department through EMS, especially if the patient is elderly or a female(4). 
 
The 2009 Update from the ACC/AHA for the triage and transfer for PCI newly 
recommends that each community develop a system of care for STEMI 
patients with specific protocols for the management and destination of those 
patients who are primary PCI candidates and are not eligible for fibrinolytic 
drugs and/or are in cardiogenic shock. It is advised that when patients arrive 
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at non-PCI-capable centers that they receive fibrinolytic therapy as the main 
source of reperfusion and be transferred, prepared with antithrombotic 
medication (an anticoagulant plus an antiplatelet), as soon as possible to a 
PCI-capable facility. 
 
2.3.6 Treatment Guidelines 
Treatment should be instated as soon as possible, but sometimes patient or 
systemic factors delay the process. Patient factors may include refusal from 
the patient(5); and although systemic factors delay the process, they do not 
result in exclusion of treatment. Guidelines from 2004-2009 provide evidence 
from recent clinical trials of the benefits of timing in treatment execution for 
STEMI patients (4, 5, 68, 69). Studies show a higher adjusted risk of in-
hospital mortality in any delays to reperfusion after arrival to the hospital.  
Figure 2-2 shows an algorithm for the recommended process of care for 
STEMI patients. 
 
Primary PCI is indicated as Class I if immediately available within the first 12 
hours of the onset of symptoms or 90 minutes or less after arrival to a PCI-
capable facility for those patients that present with Acute Coronary 
Syndrome (ACS) and ST-segment elevation in the electrocardiogram in leads 
V7 to V9 due to left circumflex arterial occlusion(5). Primary PCI is 
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considered Class IIa for selected STEMI patients older than 75 years of age. 
See appendix 2 for complete description of classifications. 
 
Aside from primary PCI, it is important to differentiate the other types of PCI 
offered. Facilitated PCI refers to access to the procedure after the 
administration of pharmacological treatment such as a high-dose heparin, 
platelet GP IIb/IIIa inhibitors, fibrinolytic therapy or a combination of the last 
two, which act as facilitators for the PCI(69). The advantage of this method 
is that it provides shorter times to reperfusion, better recovery, fewer 
adverse events and better survival rates(69).  
 
Fibrinolytic therapy works best for those patients that present early to the 
hospital after the onset of symptoms; while sometimes the clinical and 
graphic signs resolve with fibrinolytic therapy, most of the time this is not the 
case. Thus after 90 minutes of fibrinolytic therapy and a failed reperfusion, a 
rescue PCI is to be performed. Rescue PCI  has been indicated given a 
combination of clinical and electrocardiographic traces that indicate an infarct 
artery that has not reperfused, such as a maintained ST-segment 
elevated(68). 
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Figure 2-2 Algorithm of process of care for STEMI patients as recommended 
by the AHA/ACC. 
 
The recent guideline update in 2009 modified the previous recommendation 
in the triage of patients. It is now suggested that rescue PCI should be 
offered to any eligible STEMI patient,  regardless of age, since it offers the 
greatest benefit when initiated right after the onset of ischemic 
symptoms(68). Therefore elderly people that have no contraindication should 
be offered the same opportunity of receiving PCI. The recommendation does 
STEMI
PCI Capable Facility
Catheterization 
(within 90 minutes)
Patient is prepared with 
antithrombotics
(anticoagulant + antiplatelet)
Diagnostic 
Angioplasty
3 Possible Treatments:
1. Medical/Drug therapy
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3. CABG
Non PCI Capable Facility
Fibrinolisis
(door to needle within 30 min)
Transfer to PCI Capable 
Facility
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not mention any contraindications for PCI because of mental or cognitive 
status.  
 
When faced with a less than optimal scenario, such as great distances from a 
PCI-capable facility, emphasis is placed in traditional established fibrinolytic 
therapy and treatments options such as “aspirin, beta-adrenoceptor-blocking 
agents, vasodilator therapies, angiotensin converting enzyme (ACE) 
inhibitors, and cholesterol lowering therapy(4)”.  
 
 
 
 
 
  
  
28 
 
 
 
 
CHAPTER THREE 
METHODS 
3.1 Study Design 
This is a retrospective cohort study analyzing discharge data from Florida‟s 
comprehensive inpatient surveillance system for the years 2006 and 2007. 
These data includes complete coverage for all 1393 zip code areas or 67 
counties in the state of Florida for the reference years. Hospital discharge 
data were analyzed to determine if there is a disparity in the use of cardiac 
catheterization in patients 65 years of age or older with ST-Elevation 
Myocardial Infarction (STEMI) with and without a diagnosis of dementia at 
high volume PCI Florida hospitals.  
 
Although PCI is the first line of treatment for patients with STEMI, individuals 
receiving this treatment must first undergo cardiac catherization. To 
determine where in the sequence, the possible disparity between persons 
with and without dementia in usage of PCI occurs, the initial analysis was 
performed based on those that undergo cardiac catheterization to determine 
if indeed a PCI is the treatment of choice. Some patients that go through 
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cardiac catheterization may require CABG instead. Therefore secondary 
analyses were carried out to detect any possible disparities in the use of PCI 
or CABG in those patients with cardiac catheterization with and without 
dementia. To measure any gender disparities, a separate model was done to 
separate the cohort by gender.  
  
 
3.2 Study Population 
Subjects for the study were identified using the International Classification of 
Diseases (ICD), Ninth Revision, Clinical Modification (ICD-9-CM) codes. The 
ICD Clinical Modification is the official coding system used in the United 
States to code diagnoses and procedures when a patient receives services at 
a hospital or clinic and is used to classify mortality as well(70).  The database 
under study contains ten primary codes and up to 30 secondary codes using 
the referenced format.  
 
There are over 200 hospitals in Florida(66) but not all have the same 
capacity to perform Percutaneous Coronary Interventions (PCI). In order to 
reduce confounding by the facility‟s volume, only hospitals that perform high-
volume PCIs were considered in the statistical models. High volume PCI 
hospital were identified according to the American College of Cardiology and 
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the American Heart Association practice guidelines for PCI(71, 72) as those 
that perform over 400 PCIs annually.  
 
The study population consists of men and women 65 years of age and over 
admitted to a high volume PCI Florida hospital during 2006 and 2007 with a 
primary diagnosis of STEMI. Patients younger than 65 years of age were 
excluded given that dementia is prominent in the older cohort. 
 
3.2.1 Coding of main variables of interest using ICD-9-CM codes 
Subjects for the cohort were identified using the following ICD-9-CM codes: 
 Acute myocardial infarction: 410.0 - 410.6, and 410.8 with a fifth digit of 
0 or 1. The fifth digit describes the episode of care; in this case 0 
represents episode of care unspecified and 1 represents initial episode of 
care. 
 
In order to detect any disparity of care in interventions, the following 
procedural codes were used: 
 Catheterization codes: 37.21, 32.22, 37.23 
 PCI: procedure codes: 00.66, 36.01, 36.02, and 36.05.  
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 CABG codes: 36.10, 36.11, 36.12, 36.13, 36.14, 36.15, 36.16, 36.17, 
36.18, 36.19 without additional surgeries such as valvular or aortic, and 
without PCI were used. 
 Intervention: this variable was created to account for any PCI or CABG 
procedure performed on a patient. 
 
From the reference study population, a secondary code was extracted to 
categorize those with a diagnosis of dementia. This comparison group was 
identified using the following codes for dementia:  
 Persistent Mental Disorders: 294.0, 294.1, 294.8, 294.9  
 Other cerebral degenerations: 331.0-331.2, 331.7, 331.81, 331.82, 
331.89, 331.9 
 It is important to note that code 331.83 was excluded from the 
analysis because it represents mild cognitive impairment and 
these patients can be fully functional. 
 Memory loss and altered mental status: 780.93, 780.97 
 Senility without mention of dementia: 797. This code was included 
because it is commonly used as a synonym for loss of mental 
deterioration due to aging.  
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3.2.2 Coding for all other study variables 
Additional variables included in this study were as follows:  
 Socio-demographic factors  
 Gender: Male, Female (male was used as the reference category) 
 Age: this variable was first analyzed as a continuous variable and 
then categorized as follows: 
 ≥ 65 and < 75 years = Early Senior 
 ≥ 75 and < 85 years = Mid Senior 
 ≥ 85 years = Older Senior (used as reference category) 
 Ethnicity: American Indian or Alaska Native; Asian or Pacific 
Islander; Black or African American; White; White Hispanic; Black 
Hispanic; Other (if none of the ones mentioned before); or No 
Response.  
 Based on previous study findings(12), ethnicity was 
summarized for analysis under three categories: white 
non-Hispanic (used as reference category); black non-
Hispanic/African American; and Hispanic/Other. 
 Zip code Socio-Economic Status (SES) measured by proxy and was 
calculated as follows:  
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 Individual income was obtained from individual adjusted 
gross income reported on the income tax returns from the 
Internal Revenue Service‟s Individual Master File system for 
the year 2006, which includes records for every 1040, 
1040A, and 1040EZ for reporting zip code area of 
residence)(73). The mean income reported for a given zip 
code was used in the calculation for SES for that particular 
zip code. 
 On July 1st, 2006 Florida‟s total population(74) was 
18,089,888. According to the cumulative estimate of 
population change for 2006, Florida had a 13.2% change 
from 2000 to 2006(40). This percent change was used to 
calculate the population change for each zip code reported in 
the year 2000 for Florida. It is important to note that zip 
codes with census data used in this analysis were only those 
that participated in the Census 2000. 
 Given that per capita income is the most accurate method of 
measuring income in a population, the formula used to 
calculate it follows: 
[Average adjusted gross income for zip code / (Population 
reported for that income in 2000 + 13.2% population 
growth(75))]*1000 
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 Tax brackets from government statistics(76) for the year 2006 
were: 
 Tax bracket 10% = less than $7750 
 Tax bracket 15% = income greater or equal to $7550 
and less than $30650  
 Tax bracket 25% = income greater or equal to $30650 
and less than $74200 
 Tax bracket 28% = income greater or equal to $74200 
or less than $154800 
 Tax bracket 33% = income greater or equal to 
$154800 or less than $336550 
 Tax bracket 35% = income greater or equal to 
$336550 
 In order to translate the above information into a categorical 
zip code SES applicable to the cohort under study, the 
following categories were constructed: 
a) If tax bracket is in the 10% or less, it is considered zip code 
SES category 1 = income less than $7,750 
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b) If tax bracket is in the 15% it is considered zip code SES 
category 2 = income greater or equal to $7,550 but less 
than $30,650 
c) If tax bracket is greater than 25% then zip code SES 
category is 3 = income ≥ $30,650. 
 Principal Payer will be categorized as: (1) Medicare (HMO or PPO); 
(2) Self Pay, Underinsured/Charity; and (3) Other (includes 
Medicaid HMO; commercial Insurance (includes all types: HMO, 
PPO); Worker‟s Compensation; CHAMPUS; VA; Other State or Local 
Government). Category 3 was used as the reference category. 
 Source of Admission:  categories include (1) Outside the hospital 
physician Referral; (2)Transfer from a Skilled Nursing Facility; (3)ER 
Physician Recommendation; (4) Court/Law Enforcement; and (5) 
Information not available. Patients transferred from a hospital were 
not analyzed nor those who were transfers from other facility. Given 
the low number of some of these categories, the variable was re-
categorized into the following three: 
1. Referral from physician outside the hospital 
2. Recommendation from emergency room physician.  
3. Other (this category included: transfer from a skilled 
nursing facility; court/law enforcement; and information 
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not available). This category was used as reference 
category. 
 Admission Type: (1) Emergency; (2) Urgent; (3) Elective; or (4) 
Trauma.  
 Hour of Arrival: used first as a continuous variable and then 
categorized as follows: 
 00:00 - 06:00 = Early Morning 
 07:00 – 12:00 = Morning (used as reference) 
 13:00 – 17:00 = Afternoon 
 18:00 – 23:00 = Night 
 If coded „99‟    = Unknown 
 Weekday: this variable represents the day of the week the patient 
was admitted to the hospital (Monday – Sunday).  
 
3.2.3 Coding for comorbidity variables 
Comorbidity: conditions measured at time of admission using the 30 
secondary ICD-9-CM diagnosis codes in the database. Individual analysis 
were performed for comorbid risk factors listed under the AHA guidelines for 
Coronary Heart Disease and risk factors for Alzheimer‟s disease from the 
  
37 
 
Alzheimer‟s Disease Association 2010 Report(3, 12) with the following ICD-9- 
CM codes:  
 Hypertension:  401.0, 401.1, 401.9, 403, 403.0, 403.01, 403.10, 
403.11, 403.9, 403.90, 403.91 
 Diabetes: 250.00, 250.01, 250.02, 250.03, 250.10, 250.11, 
250.12, 250.13, 250.20, 250.21, 250.22, 250.23, 250.30, 
250.31, 250.32, 250.33, 250.40, 250.41, 250.42, 250.43, 
250.50, 250.51, 250.52, 250.53, 250.60, 250.61, 250.62, 
250.63, 250.70, 250.71, 250.72, 250.73, 250.80, 250.81, 
250.82, 250.83, 250.9, V58.67 
 Stroke: 430, 431, 432.0, 432.1, 432.9, 433.00, 433.01, 433.10, 
433.11, 433.20, 433.21, 433.30, 433.31, 433.80, 433.81, 
433.90, 433.91, 434.00, 434.01, 434.10, 434.11, 434.90, 
434.91, 435, 435.1, 435.2, 435.3, 435.8, 435.9, 436, 997.02, 
V12.54 
 Hyperlipidemia: 272, 272.0, 272.1, 272.2, 272.3, 272.4 
 Obesity: 278.00 
 Cigarette smoking: 305.1 
 Chronic Alcohol Abuse: 303, 303.00, 303.01, 303.02, 303.03, 
303.9, 303.90, 303.91, 303.92, 303.93, V11.3, V79.1 
 Depression:  V79.0, 300.4, 311, 296.2, 296.20, 296.21, 296.22, 
296.23, 296.24, 296.25, 296.26, 296.3, 296.30, 296.31, 296.32, 
  
38 
 
296.33, 296.34, 296.35, 296.36, 296.5, 296.50, 296.51, 296.52, 
296.53, 296.54, 296.55, 296.56 
 Chronic Kidney Disease: 404, 404.0, 404.01, 404.02, 404.03, 
404.9, 404.90, 404.91, 404.92, 404.93, 403, 403.00, 403.01, 
403.10, 403.11, 403.9, 403.90, 403.91, 585, 585.1, 585.2, 
585.3, 585.4, 585.5, 585.9 
 End Stage Renal Disease: 585.6 
 Congestive Heart Failure: 402.0, 402.00, 402.01, 402.1, 402.10, 
402.11, 402.9, 402.90, 402.91, 404, 404.0, 404.01, 404.02, 
404.03, 404.1, 404.10, 404.11, 404.12, 404.13, 404.9, 404.90, 
404.91, 404.92, 404.93, 428.0, 428.1, 428.9 
 Chronic Obstructive Pulmonary Disease: 490, 491, 491.0, 491.1, 
491.2, 491.20, 491.21, 491.22, 492, 492.0, 492.8, 
493, 493.0, 493.00, 493.01, 493.02, 493.1, 493.10, 493.11, 
493.12, 493.2, 493.20, 493.21, 493.22, 493.9, 493.90, 493.91, 
493.12, 494, 494.0, 494.1, 495, 495.0, 495.1, 495.2, 495.3, 
495.4, 495.5, 495.6, 495.7, 495.8, 495.9, 496 
Note: Heart disease is listed as a risk factor for dementia, thus the nature of 
this data. 
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3.2.4 Other variables of interest to be analyzed 
 Days to procedure (PCI and/or CABG): to properly determine the days to 
procedure it was assumed that if the principal procedure or other 
procedure had a PCI or CABG code greater than or equal to -3 and less 
than or equal to 1, the procedure took place within 24 hours thus creating 
the variables “same day PCI” or “same day CABG”. 
 Length of hospital stay: this variable represents the number of days from 
when the patient was admitted to discharge. To analyze this variable 
those patients that passed away while hospitalized were excluded from 
the analysis. 
 
3.3 RESEARCH QUESTIONS  
3.3.1 Main Research Question 
Is there disparity in the use of cardiac catheterization for ST-Myocardial 
Infarction patients with a diagnosis of dementia versus patients without a 
diagnosis of dementia after controlling for the following patient and hospital 
factors: age; gender; ethnicity; zip code SES; year of hospital admission; 
hour of arrival at the emergency department; source of admission; principal 
payer and the following comorbidities: hypertension (HTN), diabetes mellitus 
type 2 (DM), stroke (STRK), hyperlipidemia (HLP), obesity, smoking history 
(SMK), depression (DEP), end stage renal disease (ESRD), chronic kidney 
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disease (CKD), congestive heart failure (CHF), chronic obstructive pulmonary 
disease (COPD) and chronic alcohol abuse (OH)?  
 
3.3.2 Secondary Research Questions 
1. Is there is a difference in PCI use between STEMI patients with and 
without dementia who underwent cardiac catheterization after controlling 
for the following patient and hospital factors: age; gender; ethnicity; zip 
code SES; year of hospital admission; hour of arrival at the emergency 
department; source of admission; principal payer and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic abuse (OH)? 
 
2. Is there is a disparity of CABG use between STEMI patients with and 
without dementia who underwent cardiac catheterization after controlling 
for the following patient and hospital factors: age; gender; ethnicity; zip 
code SES; year of hospital admission; hour of arrival at the emergency 
department; source of admission; principal payer and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
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(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH)? 
 
 
3. Is there is a difference between the days to procedure (PCI or CABG) for 
STEMI patients with and without dementia after controlling for the 
following patient and hospital factors: age; gender; ethnicity; zip code 
SES; year of hospital admission; hour of arrival at the emergency 
department; source of admission; principal payer and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic abuse (OH)?  
 
4. Does having dementia affects the length of hospital stay for STEMI 
patients after controlling for the following patient and hospital factors: 
age; gender; ethnicity; zip code SES; year of hospital admission; hour of 
arrival at the emergency department; source of admission; principal 
payer and the following comorbidities: hypertension (HTN), diabetes 
mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP), obesity, 
smoking history (SMK), depression (DEP), end stage renal disease 
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(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF), 
chronic obstructive pulmonary disease (COPD) and chronic abuse (OH)? 
 
3.4 Statistical Analysis 
Data analysis was performed using Statistical Analysis Software (SAS®) 
version 9.1.2 software program. De-identified data were provided by year in 
separate SAS files and merged to one main data set containing all necessary 
information for the analysis for the years 2006 and 2007.  
 
Before starting the study, a feasibility sample size was performed using a PS 
program that works in Microsoft Windows operating system(77). Sample size 
and power analysis was based on study by Sloan et al. (2004)(78).  
 
Based on the literature review (78-80), it is expected that patients with a 
diagnosis of dementia have a lower probability of receiving cardiac 
catheterization. The assumption is that the failure rate is 0.15 or 15% of 
non-demented STEMIs receiving PCI. The risk ratio of PCI in people with 
dementia that had STEMIs is less than or equal to 0.6, “m” represents the 
ratio of non-demented patients with STEMI, which are treated as the 
unexposed to demented patients with STEMI, considered as the exposed. 
Applying Sloan and colleagues‟ analysis, „m‟ would be 21.06, this is the ratio 
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of unexposed to exposed subjects, and the relative risk of failure for exposed 
subjects relative to unexposed „R‟ is 0.267. 
 
Therefore, given that the PS program used assumes two-tailed tests, alpha 
will be set at 0.1 corresponding to alpha 0.05 for a one-tailed test.  Since for 
this analysis the outcome can only take one of two values, received 
procedure or not, an uncorrected chi-square test was performed to evaluate 
the null hypothesis.  
3.4.1 Sample Size and Power Analysis 
This study was planned as a retrospective cohort study with 21.06 
unexposed subjects per group. Prior data(78) indicate that the failure rate 
among unexposed is 0.15. If the true relative risk of failure for exposed 
subjects relative to unexposed is 0.267, we need to study 49 exposed 
subjects and 1031.94 unexposed subjects to be able to reject the null 
hypothesis that this relative risk equals 1 with probability (power) 0.8. The 
Type I error probability associated with this test of this null hypothesis is 0.1. 
 
3.4.2 Stratified Analysis  
Baseline characteristics of the population were first analyzed by tabulating 
the frequency of admission characteristics and comorbid conditions.  
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Stratified by analyses by dementia status were carried out to identify 
potential confounders among the following variables: 
1. Age: Multiple meta-analysis studies have demonstrated the link 
between age and dementia(8, 30) and between age and heart 
disease(3). 
2. Gender: Some studies have demonstrated that females are more likely 
to suffer from dementia(29, 30) and more males than females seem to 
have PCI (66).  
3. Ethnicity: Black patients are known to receive PCI less often than 
whites(7, 66).  
4. Socio-economic status: there is no conclusive data on whether the 
prevalence and incidence of dementia is higher in low socioeconomic 
environments, the incidence of PCI has been found to be lower for 
those with a disadvantaged SES class(67). 
5. Year of hospital admission: to determine if there was improvement of 
care over time. 
6. Hour of arrival at the emergency department: Many studies indicate the 
association of arrival time and possible PCI(68). 
7. Source of Admission: Patients who arrive at the hospital using the 
emergency medical services have better survival rates(4). 
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8. Principal Payer: patients with commercial insurance seem to receive 
better care than Medicare beneficiaries(81). 
9. Hospital PCI volume category: Hospitals with high volume PCI tend to 
have less disparity of care in PCI(71). 
10. Comorbidities of importance in the association between dementia and 
STEMI were: hypertension; hyperlipidemia; obesity; smoking status; 
chronic alcohol abuse; diabetes mellitus type II; depression; stroke; 
end stage renal disease; chronic kidney disease; congestive heart 
failure; chronic obstructive pulmonary disease. 
 
Patients were also stratified by gender and according to the presence of each 
of the previously mentioned risk factors: hypertension, hyperlipidemia, 
obesity, diabetes, stroke, cigarette smoking, alcohol abuse, depression, 
chronic kidney disease (CKD), end stage renal disease (ESRD), congestive 
heart failure (CHF) and chronic obstructive pulmonary disease (COPD).  
 
Chi-square tests were used for discrete variables and t-tests for continuous 
variables when comparing those with and without a diagnosis of dementia. 
Age-adjusted relative risks and 95% confidence intervals were estimated 
when comparing the groups using logistic regression procedures. 
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Univariate models were performed to look at the distribution of continuous 
risk factors for STEMI and dementia (age, length of hospital stay and SES) as 
it provides the most descriptive statistics.  
 
3.4.3 Statistical Models 
3.4.3.1 Main Research Question Model 
To address the main research question, multivariate logistic regression 
analysis was performed to examine any differences in the use of diagnostic 
cardiac catheterization for STEMI patients with and without a diagnosis of 
dementia:  
 
Model 1:  
Logit=Log (px/(1-px))= α + 1dementia 
 
where px is the probability of the x
th STEMI patient receiving diagnostic 
cardiac catheterization 
 
The second model used adjusts for all potential confounders and provides 
data related to the independent effects of each variable: age category, 
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gender, ethnicity, zip code socio-economic status (SES), year of 
hospitalization, hour of arrival, source of admission, type of payer, and the 
following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), 
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), 
depression (DEP), end stage renal disease (ESRD), chronic kidney disease 
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
Model 2: 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
where px is the probability of the x
th STEMI patient receiving diagnostic 
cardiac catheterization. 
 
Model three was done not adjusting for zip code SES but adjusted for all 
other potential confounders and provided data related to the independent 
effects of each variable: age category, gender, ethnicity, year of 
hospitalization, hour of arrival, source of admission, type of payer, and the 
following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), 
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), 
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depression (DEP), end stage renal disease (ESRD), chronic kidney disease 
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 3:  
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer 
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD  
where px is the probability of the x
th STEMI patient receiving diagnostic  
cardiac catheterization. 
 
3.4.3.2 Secondary Research Question Models 
3.4.3.2.1 Secondary question #1 models 
To address the first secondary question, models four to six were run to 
examine any differences in the use of PCI for STEMI patients who underwent 
diagnostic cardiac catheterization with and without a diagnosis of dementia.  
Model 4: 
Logit=Log (px/(1-px))= α + 1dementia 
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where px is the probability of the x
th cardiac catheterized STEMI patient 
receiving PCI. 
 
Model five was done adjusting for all potential confounders and provides data 
related to the independent effects of each variable: age category, gender, 
ethnicity, zip code socio-economic status (SES), year of hospitalization, hour 
of arrival, source of admission, type of payer, and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 5: 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
where px is the probability of the x
th cardiac catheterized STEMI patient 
receiving PCI. 
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Model six adjusted for all other potential confounders except zip code SES 
and provided data related to the independent effects of each variable: age 
category, gender, ethnicity, year of hospitalization, hour of arrival, source of 
admission, type of payer, and the following comorbidities: hypertension 
(HTN), diabetes mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP), 
obesity, smoking history (SMK), depression (DEP), end stage renal disease 
(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF), 
chronic obstructive pulmonary disease (COPD) and chronic alcohol abuse 
(OH). 
 
Model six:  
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer 
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD  
where px is the probability of the x
th cardiac catheterized STEMI patient 
receiving PCI. 
 
3.4.3.2.2 Secondary question #2 models 
To address the second secondary question, model seven was run to examine 
any disparity in the use of CABG for STEMI patients who underwent 
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diagnostic cardiac catheterization with and without a diagnosis of dementia 
as follows: 
Model 7: 
Logit=Log (px/(1-px))= α + 1dementia 
where px is the probability of the x
th cardiac catheterized STEMI patient 
receiving CABG. 
 
Model eight was done adjusting for all potential confounders and provided 
data regarding the independent effects of each variable: age category, 
gender, ethnicity, socio-economic status (SES), year of hospitalization, hour 
of arrival, source of admission, type of payer, and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 8: 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
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9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
where px is the probability of the x
th cardiac catheterized STEMI patient 
receiving CABG. 
 
Model nine did not adjust for zip code SES but it did adjust for all other 
potential confounders and provided data regarding the independent effects of 
each variable: age category, gender, ethnicity, year of hospitalization, hour 
of arrival, source of admission, type of payer, and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 9:  
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer 
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD  
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where px is the probability of the x
th cardiac catheterized STEMI patient 
receiving CABG. 
 
3.4.3.2.3  Secondary question #3 models 
In order to determine if there was a difference between the days to 
procedure for either PCI or CABG, for STEMI patients with and without 
dementia, models ten to fifteen were run. The variable days to procedure 
was dichotomized as performed within 24 hours or else. 
 
Model 10: 
Logit=Log (px/(1-px))= α + 1dementia 
where px is the probability of x
th days to PCI for cardiac catheterized STEMI 
patient. 
 
Model eleven was done adjusting for all potential confounders and provided 
data regarding the independent effects of each variable: age category, 
gender, ethnicity, socio-economic status (SES), year of hospitalization, hour 
of arrival, source of admission, type of payer, and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
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(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 11: 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
where px is the probability of x
th days to PCI for cardiac catheterized STEMI 
patient. 
 
Model twelve did not adjust for zip code SES but it did adjust for all other 
potential confounders and provided data regarding the independent effects of 
each variable: age category, gender, ethnicity, year of hospitalization, hour 
of arrival, source of admission, type of payer, and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
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Model 12:  
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer 
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD  
where px is the probability of x
th days to PCI for cardiac catheterized STEMI 
patient. 
 
Model thirteen is based on model ten but here the probability of days to 
CABG is being measured. 
 
Model 13: 
Logit=Log (px/(1-px))= α + 1dementia 
where px is the probability of x
th days to CABG for cardiac catheterized STEMI 
patient. 
 
Model fourteen was done adjusting for all potential confounders and provided 
data regarding the independent effects of each variable: age category, 
gender, ethnicity, zip code socio-economic status (SES), year of 
hospitalization, hour of arrival, source of admission, type of payer, and the 
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following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), 
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), 
depression (DEP), end stage renal disease (ESRD), chronic kidney disease 
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 14: 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
where px is the probability of x
th days to CABG for cardiac catheterized STEMI 
patient. 
 
Model fifteen did not adjust for zip code SES but it did adjust for all other 
potential confounders and provided data regarding independent effects of 
each variable: age category, gender, ethnicity, year of hospitalization, hour 
of arrival, source of admission, type of payer, and the following 
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke 
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression 
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD), 
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congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH). 
 
Model 15:  
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer 
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD  
where px is the probability of x
th days to CABG for cardiac catheterized STEMI 
patient. 
 
3.4.3.2.4 Secondary question #4 models 
To address the last secondary question, models sixteen though eighteen 
were run to identify if having dementia affects the length of hospital stay for 
STEMI patients. A Cox‟ proportional hazards regression model was chosen 
because it is able to explain the effect of several risk factors on time until 
discharge from hospital(82).  A comparison of hospitalization length of stay 
between patients with dementia and patients without dementia was 
performed as follows: 
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Model 16: 
H(t) = H0(t) x exp(1dementia) 
H0(t) is the baseline hazard at time t, representing the hazard for a person 
without dementia. 
To explain the effect of comorbidity on time (discharge from hospital), the 
following two models were executed. Model 17 adjusts for the zip code socio-
economic status proxy variable (SES) and model 18 does not adjust for the 
zip code socio-economic status proxy. 
 
Model 17:  
H(t) = H0(t) x exp(1dementia +2age  category + 3gender + 4ethnicity + 
5SES + 6year of admission + 7hour of arrival + 8source of admission + 
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD) 
H0(t) is the baseline hazard at time t, representing the hazard for a person 
with the value 0 for all the predictor variables. 
 
Model 18: 
H(t) = H0(t) x exp(1dementia +  2age  category + 3gender + 4ethnicity + 
5year of admission + 6hour of arrival + 7source of admission + 8payer + 
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9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 16DEP 
+ 17ESRD + 18CKD + 19CHF + 20COPD) 
 
3.4.3.3 Sensitivity analysis for definition of dementia 
A sensitivity analysis was conducted to determine if it is appropriate or not to 
use the broad definition of dementia, as used in model 2, compared to the 
strict or more specific definition of Alzheimer‟s disease. This modeling was 
done to determine how dependent the definitions were. All those in the 
cohort with dementia were first identified (model 2), then those with a 
diagnosis of Alzheimer‟s disease (model 19), and finally a third model with 
those with dementia but no Alzheimer‟s (model 20). 
 
Model 19 was done using logistic regression to compare dementia as main 
exposure and diagnostic cardiac catheterization as outcome for those 
patients with a diagnosis of dementia type Alzheimer‟s. And model 20 
compared non-Alzheimer‟s dementia as main exposure and diagnostic cardiac 
catheterization as outcome. 
 
Model 19: 
 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
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9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
 
where px is the probability of x
th STEMI Alzheimer‟s disease dementia patient 
receiving diagnostic cardiac catheterization. 
 
Model 20:  
 
Log [px/(1-px)]=0 + 1dementia +  2age  category + 3gender + 4ethnicity 
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission + 
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK + 
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD  
where px is the probability of x
th STEMI non-Alzheimer‟s demented patient 
receiving diagnostic cardiac catheterization. 
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CHAPTER 4 
RESULTS 
4.0 Descriptive Statistics 
4.1 Characteristics of the Cohort 
The Florida hospital inpatient surveillance system database for the years 
2006 and 2007 contained data for 13,148 STEMI patients over 65 years of 
age for the years 2006 and 2007. After restricting the cohort to only those 
seen at high volume PCI facilities, 8,331 STEMI patients were eligible for 
analysis.  Table 4-1 describes the characteristics of the cohort in detail. 
 
There were 7.3% (n=605) of patients with a diagnosis of dementia and of 
these, 32.7% (n=198) were diagnosed with Alzheimer‟s disease. Most 
patients were early senior white males (n=2060).The majority of patients, 
85.4% (n=7112) were admitted through the emergency department and 
79.4% (n=6615) were coded as emergencies. There were no differences in 
distribution by time or day of the week admitted to the hospital.  
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Table 4-1 Baseline Characteristics of Elderly STEMI Patients in Florida during 
2006-2007. 
 
 Total cohort 
%(N=8,331) 
Patients without 
Dementia 
%(N=7726) 
Patients with 
Dementia 
%(N=605) 
P Value 
for 
difference 
Age Category 
65-74 
75-84 
85+  
 
 
45.71%  (3808) 
37.03% (3085) 
  17.26% (1438) 
 
48.40% (3739) 
36.76% (2840)  
 14.85% (1147) 
   
11.40% (   69) 
40.50%( 245)  
48.10% ( 291)  
 
P<0.0001 
Gender 
Men 
Women  
 
 
56.73% (4726) 
43.27% (3605) 
 
58.02% (4483) 
41.98% (3243) 
 
40.17% ( 243)  
59.83% ( 362)  
 
P<0.0001 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic & Others  
 
 
83.38% (6946) 
4.65% (  387) 
11.98% (  998) 
 
83.57% (6457) 
  4.44% (  343)     
11.99% (  926)   
 
80.83% ( 489) 
  7.27% (   44)  
11.90% (  72 ) 
 
P=0.0061 
Payer 
Medicare 
Self Pay/Charity 
Other 
 
 
89.86% (7486) 
1.03% (    86) 
9.11% (  759) 
 
89.50% (6915) 
1.09% (    84) 
9.41% (  727) 
 
94.38% ( 571) 
0.33% (     2) 
5.29% (   32) 
 
P=0.0005 
Received Diagnostic 
Cardiac Catheterization 
 
77.24% (6435) 79.63% (6152) 46.78% ( 283) P<0.0001 
Received PCI 
 
67.16% (5595)  69.29% (5353) 40.00% ( 242) P<0.0001 
Received CABG 
 
9.33% (  777) 9.77% (  755)   3.64% (   22) P<0.0001 
Length of Hospital Stay* 5.99 ( 5.90)  5.98 ( 5.93)  6.09 ( 5.55)  P=0.0384 
Risk Factors 
Hypertension 
Diabetes Mellitus 
Stroke 
Hyperlipidemia 
Obesity 
Smoking 
Alcohol abuse 
Depression 
Chronic Kidney Disease 
End Stage Renal Disease 
Congestive Heart Failure 
Chronic Obstructive 
Pulmonary Disease 
 
67.72% (5642) 
29.08% (2423) 
4.89% (  407) 
56.28% (4689) 
6.51% (  542) 
12.86% (1071) 
0.54% (    45) 
5.40% (  450) 
14.38% (1198) 
1.42% (  118) 
29.77% (2480) 
21.21% (1767) 
 
 
67.87% (5244) 
29.21% (2257) 
4.71% (  364) 
57.33% (4429) 
6.76% (  522) 
13.47% (1041) 
0.54% (    42) 
4.72% (  365) 
13.85% (1070) 
1.40% (  108) 
28.86% (2230) 
21.14% (1633) 
 
65.79% ( 398) 
27.44% ( 166) 
7.11% (   43) 
42.98% ( 260) 
3.31% (   20) 
4.96% (   30) 
0.50% (     3) 
14.05% (   85) 
21.16% ( 128) 
1.65% (   10) 
41.32% ( 250) 
22.15% ( 134) 
 
P=0.2898 
P=0.3546 
P=0.0085 
P<0.0001 
P=0.0009 
P<0.0001 
P=0.8774 
P<0.0001 
P<0.0001 
P=0.6092 
P<0.0001 
P=0.5575 
*Continuous data are mean (SD)  
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4.1.1 Age 
The average age of the sample was 76.30 years (SD 7.85; 95% CI SD 7.73 -
7.97) (Table 4-1).  Figure 4-1shows the age distribution of cohort. For 
practical comparisons, the cohort was categorized into three age groups 
commonly used in the literature: early seniors (65-74 years old), mid-seniors 
(75-84 years) and seniors over 85 years of age. Most of the sample were in 
the early senior category 45.7% (n=3808) and the least number of subjects 
were over the age of 85, 17.3% (n=1438).   
 
Males comprised most of the early seniors 66.8% (n=2544) while females 
the older senior group 61.5% (n=885). There was a crossover effect at 78 
years of age (Figure 4-2); 48.4% (n=3739) of non-demented patients were 
in the early senior category while 48.1% (n=291) of those with dementia 
were in the oldest old category, over 85 years of age. 
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Figure 4-1 Age distribution of Elderly STEMI patients in Florida during 2006-
2007. 
 
 
Figure 4-2 Age distribution of Elderly STEMI patients in Florida during 2006-
2007 by Dementia Status. Percent of STEMI patients is shown for each 
diagnostic category  
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4.1.2 Ethnicity 
 
The majority of the cohort were white non-Hispanic 83.4% (n=6946) (Table 
4-2) followed by 12.0% (n=998) Hispanics/Other. Most of the non-Hispanic 
whites and Hispanics/Other were males 56.4% (n=3917) and 61.82% 
(n=617) respectively. Blacks accounted for the minority of the cohort but 
were more evenly distributed by gender; black females accounted for 50.4% 
(n=195) of that sample. However in the Hispanic/other category there were 
24% fewer females than males. 
 
Table 4-2 Ethnic Characteristics of Elderly STEMI Patients in Florida during 
2006-2007. 
 
Ethnicity 
Males 
%(n=4726) 
Females 
%(n=3605) 
Early Senior 
%(n=3808) 
Mid Senior 
%(N=3085) 
Older Senior 
%(N=1438) 
White Non-
Hispanic 
83.4%(6946) 
 
82.9%(3917) 84.0%(3029) 
 
80.7%(3074) 84.7%(2614) 87.5%(1258) 
Black Non-
Hispanic 
4.6%(387) 
 
4.1%(192) 5.4%(195)  5.7%(217)  4.0%(125)  3.1%(45) 
Hispanic/ 
Others 
12.0%(998) 
13.1%(617) 10.6%(381) 13.6%(517)   11.2%(346) 9.4%(135) 
 
Black non-Hispanics received the least number of interventions and had the 
lowest prevalence of depression, but had the highest prevalence of dementia, 
Alzheimer‟s, obesity, hypertension, diabetes, chronic kidney disease, end 
stage renal disease, congestive heart failure and current or history of 
smoking than any other ethnic category(Figure 4-3). 
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4.1.3 Comorbidity of the Cohort 
Over two thirds of the cohort was hypertensive (67.7% n=5642); demented 
patients were slightly less hypertensive 65.8% (n=398). When stratified by 
ethnicity Black/African American non-Hispanics had the highest prevalence of 
hypertension (80.1% n=310). Refer to Figure 4-3 for specific comorbidities 
of the cohort by ethnicity.  
 
There were 2423 coded diabetics in the cohort (29.1%), of these 29.2% 
(n=2257) were non-demented patients and 27.4% (n=166) were demented 
patients. Forty five percent of Black/African American non-Hispanics were 
diabetic (n=173) and 26.4% (n=102) had chronic kidney disease (CKD). 
Overall there were 14.4% (n=1198) of patients in the cohort with a diagnosis 
of CKD; demented patients had the highest prevalence of CKD, 21.2% 
(n=128). Only 1.4% (n=118) of patients in the cohort had end stage renal 
disease (ESRD), however demented patients had the highest prevalence 
(1.6% n=10) and when stratified by ethnicity, Blacks had the highest 
prevalence (5.7% n=22). 
 
Over half of the cohort was hyperlipidemic (56.3% n=4689) yet only 6.5% 
(n=542) of the cohort was obese. Non-demented patients had the highest 
prevalence of hyperlipidemia, 57.3% (n=4429). White non-Hispanics had the 
highest number of hyperlipidemics, 57.4% (n=3986).  
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Twenty one percent of the cohort (n=1767) were coded as having chronic 
obstructive pulmonary disease (COPD) and 21.6% (n=1500) of whites 
carried the diagnosis. Almost 13% (n=1071) of the cohort had a history of 
smoking or were current smokers, of these non-demented patients smoked 
the most 13.5% (n=1041). When stratified by ethnicity, Black/African 
American non-Hispanics smoke or smoked the most, 13.7% (n=53).  Very 
few people in the cohort were chronic alcoholics, 0.5% (n=45). 
 
Only 4.9% (n=407) of the patients in the cohort had a history of a stroke or 
had a current stroke; however 7.1% (n=43) of demented patients and 5% 
(n=350) of White non-Hispanics had the highest prevalence. There were 
5.4% (n=450) patients in the cohort with a diagnosis of depression; 14% of 
demented patients were depressed compared to 4.7% of non-demented 
patients and Hispanics/Other had the highest prevalence of depression from 
all other ethnic groups, 6.2% (n=62). 
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*ESRD (End Stage Renal Disease), CKD (Chronic Kidney Disease), COPD (Chronic Obstructive Pulmonary 
Disease), CHF (Congestive Heart Failure), DM (Diabetes Mellitus), HLP (Hyperlipidemia), HTN 
(Hypertension). 
 
Figure 4-3 Prevalence of Comorbidities among STEMI patients by ethnicity.  
 
4.1.4 Source and Days of Admissions 
The source of most admissions was through emergency room 85.4% 
(n=7112) and as referrals 13.9% (n=1155). There were no significant 
differences for source of admission by gender, age category, ethnicity, or day 
of admission. Demented patients were more likely to be admitted on Friday 
17.2% (n=104) but this was not significant when compared to non-
demented patients (Table 4-3).  
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Table 4-3 Day of Week of Hospital Admission for STEMI Patients with and 
without dementia in Florida during 2006-2007. 
 
Day of 
Admission 
Total cohort 
%(N=8,331) 
Patients without 
Dementia 
%(N=7726) 
Patients with 
Dementia 
%(N=605) 
P Value 
for 
difference 
Monday 15.1% (1257) 15.0% (1162) 15.7% (95) P=0.7344 
Tuesday 14.1% (1176) 14.1% (1090) 14.2% (86) 
Wednesday 15.0% (1249) 15.1% (1167) 13.5% (82) 
Thursday 13.8% (1151) 13.8% (1069) 13.5% (82) 
Friday 15.0% (1252) 14.9% (1148) 17.2% (104) 
Saturday 13.3% (1109) 13.4% (1034) 12.4% (75) 
Sunday 13.6% (1137) 13.7% (1056) 13.4% (81) 
 
4.1.5 Type of Admissions and Payer 
Most type of admissions were emergencies 79.4% (n=6615). There were no 
major differences in type of admission by payer, gender or dementia status. 
Payment distribution was allocated into three categories: Medicare payers, 
self-pay or charity, and other means including commercial insurance.  Nearly 
everyone paid through Medicare 89.9% (n=7486); 9.1% (n=759) paid 
through other means and only 1.0% (n=86) were self-pay. 
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4.1.6 Length of Hospital Stay 
The mean length of the hospital stay for survivors in the cohort was 6.2 days 
(SD 5.9; 95% CI 6.05-6.35; p<0.0001). Table 4-4 shows detail data for this 
variable by dementia status. Females had slightly longer hospital stays than 
males (6.32 days vs. 6.07 days). Most females (40.0% n=1261) stayed 4-7 
days in the hospital while the majority of males (39.1% n=1667) stayed for 
2-3 days p<0.0001.  
 
Table 4-4 Length of Hospital Stay for survivor STEMI Patients with and 
without dementia in Florida during 2006-2007. 
 
Length 
 
Total 
survivors 
%(N=7422) 
 
Patients 
without 
Dementia 
%(N=6921) 
 
Patients with 
Dementia 
%(N=501) 
 
P Value 
for 
difference 
Less or equal 1 day 2.9%(216) 2.9%(201) 3.0%(15) 
 
<0.0001 
Within 2-3 days 36.0%(2671) 36.8%(2547) 24.7%(124) 
Within 4-7 days 36.5%(2708) 36.0%(2490) 43.5%(218) 
Within 8- 14 days 17.6%(1309) 17.4%(1203) 21.2%(106) 
Within 15-30 days 5.8%(433) 5.8%(401) 6.4%(32) 
Greater than 1 month 1.15%(85) 1.1%(79) 1.2%(6) 
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4.2 Outcomes for Cardiovascular Interventions 
 
 
Figure 4-4 Percent of STEMI patients who received interventions in Florida 
during 2006-2007. 
 
Over three quarters of STEMI patients in the cohort received diagnostic 
cardiac catheterization, 77.2% (n=6435); slightly more than two thirds, 
67.2% (n=5595) underwent PCI and 9.3% (n=777) received CABG (Figure 
4-4). When looking only at those who received catheterizations, 73.8% 
(n=6150 p=<0.0001) received some form of intervention, either PCI or 
CABG. Sixty percent of the cohort (n=4986) received PCI on the same day of 
admission and 5.4% (n=449) received CABG. In general, those in the older 
group, patients with dementia, and females were less likely to receive any 
kind of intervention. Figures 4-4 to 4-11 show the distribution of 
interventions by different variables of interest. 
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Figure 4-5 Percent of STEMI patients who received interventions by 
dementia status. 
 
 
 
Figure 4-6 Percent of STEMI patients who received interventions by gender. 
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Figure 4-7 Percent of STEMI patients who received interventions by age 
category. 
 
Overall the very old, those over the age of 85, received 30% fewer 
interventions (diagnostic cardiac catheterization or PCI) than the early 
seniors (Figure 4-7). When stratifying the age categories by dementia status 
the percent of STEMI patients who received catheterization or PCI was the 
same. 
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Figure 4-8 Percent of STEMI patients who received diagnostic cardiac 
catheterization by age category and dementia status. 
 
 
Figure 4-9 Percent of STEMI patients who received PCI by age category and 
dementia status. 
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Figure 4-10 Percent of STEMI patients who received CABG by age category 
and dementia. 
 
 
Figure 4-11 Percent of STEMI patients who received interventions by SES 
category.  
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4.3 Comorbidities and Use of Interventions 
 
 
*Alcohol (Current Alcohol abuse), ESRD (End Stage Renal Disease), DEP (Depression), CKD (Chronic 
Kidney Disease), Smoking (Current Smoking), COPD (Chronic Obstructive Pulmonary Disease), CHF 
(Congestive Heart Failure), DM (Diabetes Mellitus), HLP (Hyperlipidemia), HTN (Hypertension). 
 
Figure 4-12 Prevalence of Comorbidities for STEMI patients in Florida by age 
category.  
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12% currently smoked or had a history of smoking, 33.5% were diabetic and 
62% were hyperlipidemic.  
 
Table 4-5 Characteristics of hypertensive STEMI patients in Florida during 
2006-2007. 
 
 Patients with 
Hypertension  
% (n=5642) 
Patients without 
Hypertension  
% (n=2689) 
Chi-square 
Probability 
Gender  
Men  
Women  
 
54.50% (3075) 
45.50% (2567)  
 
61.40% (1651) 
38.60% (1038) 
 
p<0.0001  
Ethnicity  
White non-Hispanic  
Black non-Hispanic  
Hispanic & Others  
 
82.17% (4636) 
5.49% (  310) 
12.34% (  696)  
 
85.91% (2310) 
2.86% (    77) 
11.23% (  302) 
 
p<0.0001  
Received Cardiac 
Catheterization  
76.85% (4336)  78.06% (2099) p=0.2194  
Received PCI  66.55% (3755)  68.43% (1840) p=0.0889 
Received CABG  9.38% (  529)  9.22% (  248) p=0.8220 
Other Medical 
Conditions 
Dementia 
Alzheimer’s  
Diabetes Mellitus  
Stroke  
Hyperlipidemia  
Obesity  
Smoking  
Alcohol abuse  
Depression  
Chronic Kidney Disease  
End Stage Renal 
Disease  
Congestive Heart 
Failure  
COPD  
 
 
7.05% (  398) 
2.23% (  126) 
33.55% (1893) 
5.41% (  305) 
61.93% (3494) 
7.71% (  435) 
12.00% (  677) 
0.41% (    23) 
5.99% (  338) 
17.81% (1005) 
1.84% (  104) 
 
9.23% (1649) 
 
21.64% (1221) 
 
 
7.70% (  207) 
2.68% (    72) 
19.71% (  530) 
3.79% (  102) 
44.44% (1195) 
3.98% (  107) 
14.65% (  394) 
0.82% (    22) 
4.17% (  112) 
7.18% (  193) 
0.52 (    14) 
 
30.90% (  831) 
 
20.30% (  546) 
 
 
p=0.2898 
p=0.2132 
P<0.0001 
P=0.0014 
P<0.0001 
P<0.0001 
P=0.0007 
P=0.0169 
P=0.0006 
P<0.0001 
P<0.0001 
 
P=0.1177 
 
P=0.1630 
 
4.3.2 Hyperlipidemia 
Over half of the cohort was hyperlipidemic 56.3% (n=4689). Most were early 
and mid seniors (51.78% and 35.2% respectively) and 57.9% were males 
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(see figure 4-12). Of all the patients with high lipids, a total of 82% received 
cardiac catheterization (OR 1.85, 95% CI 1.67-2.06) and 71.8% received PCI 
(OR 1.61, 95% CI 1.47-1.77).  There was no significant difference in 
receiving CABG for those with and without hyperlipidemia. Only 5.5% (OR 
0.56, 95% CI 0.47-0.66) of the hyperlipidemics had dementia and 1.7% (OR 
0.52, 95% CI 0.39-0.69) had a diagnosis of Alzheimer‟s disease. 
 
Patients with hyperlipidemia were 1.5 times more likely to have diabetes 
(95% CI 1.33-1.61), two times as likely (OR 2.03, 95% CI 1.85-2.23) to 
have hypertension, 1.9 times more likely to be obese (95% CI 1.58-2.31) 
than non-hyperlipidemics and smoked 20% more than patients without high 
lipids. However depression was not significant for these patients (OR 1.04, 
95% CI 0.86-1.27) and they were less likely to have chronic kidney disease 
(OR 0.86 95% CI 0.76-0.97), end stage renal disease (OR 0.44, 95% CI 
0.30-0.64), congestive heart failure (OR 0.73, 95% CI 0.66-0.80) and less 
COPD (OR 0.81, 95% CI 0.73-0.90). 
 
4.3.3 Diabetes Type 2 
Over a quarter of the cohort was diabetic, 29.1% (n=2423) and of these 
76.1% received cardiac catheterization; however diabetics were 0.78 times 
less likely to receive PCI than non-diabetics (95% CI 0.70-0.86) but 1.4 
times more likely to go through CABG (95% CI 1.19-1.62).  Gender was not 
a significant factor for diabetes. Early seniors were 36% more diabetic than 
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older seniors (49% vs. 13%). More Black non-Hispanic/African American 
44.7% (n=173) were diabetics than any of the other ethnic groups. 
Dementia was not a significant factor for having diabetes (OR 0.92, 95% CI 
0.76-1.10).   
 
Two thirds of the diabetics had high lipids (OR 1.46 95% CI 1.33-1.61); they 
were 2.1 times more likely to have hypertension (95% CI 1.84-2.30); 2.4 
times more likely to be obese (95% CI 2.03-2.88) and much more likely to 
have end stage renal disease (OR 2.84, 95% CI 1.97-4.09) and chronic 
kidney disease (OR 2.07, 95% CI 1.83-2.35). Diabetics were also 1.5 times 
more likely than non-diabetics to have congestive heart failure. Nonetheless, 
they were less likely to smoke than non-diabetics (OR 0.80, 95% CI 0.59-
0.93). 
 
4.3.4 Stroke 
Roughly 5% of the cohort (n=407) had had either current stroke or history of 
stroke.  Females had 2% more history or current strokes than males 50.9% 
versus 49.1% respectively (OR 0.72, 95% CI 0.59-0.88) and mid-seniors had  
more history or current strokes than seniors over 85 years of age, 41.77% 
vs. 19.90% (p<0.009).  Ethnicity was not a statistically significant factor for 
patients with or without a current stroke or medical history of one 
(p=0.3004).  
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Patients with a history of or current stroke were 0.5 times less likely to have 
cardiac catheterizations than those without strokes (95% CI 0.42-0.63) and 
0.4 times less likely to receive PCI (95% CI 0.37-0.55); however, they were 
more likely to receive CABG than those without a current stroke or history of 
one (OR 1.45, 95% CI 1.08-1.96).  Patients with dementia had had 2.4% 
more history or current strokes than non-demented patients, 7.11% vs. 
4.71% (OR 1.55, 95% CI 1.11-2.15). 
 
Seventy five percent of patients with a history of or current stroke had 
hypertension (OR 1.45, 95% CI 1.15-1.82) and were more likely to be 
depressed (OR 1.48, 95% CI 1.01-2.16) although this was not statistically 
significant; these patients were more likely to have COPD (OR 1.59, 95% CI 
1.28-1.98), chronic kidney disease (OR 1.80, 95% CI 1.41-2.29), and 
congestive heart failure (OR 1.98, 95% CI 1.62-2.42) than those without a 
current stroke or history of one.   
 
4.3.5 Smoking and Alcohol abuse 
Roughly one eighth (12.9% n=1071) of the sample currently smoked or had 
smoked.  Most smokers were in the early senior category (70.6% n=756) 
and were males (62.4% n=668).  Blacks/African Americans non-Hispanics 
were the ethnic group that smoked the most (13.7%). Eighty eight percent 
of smokers were catheterized, 77.6% received PCI, and 11.5% went through 
CABG (Figure 4-13). Non-demented patients smoked much more than those 
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with dementia (13.5% vs 4.96%) and only 3.0% of the patients diagnosed 
with Alzheimer‟s disease were smokers. Almost two thirds of smokers were 
hypertensive (63.21% n=677) and 60% (n=644) had hyperlipidemia (OR 
1.20, 95% CI 1.05-1.37). Smokers were 5.5 times more likely than non-
smokers to use alcohol (95% CI 3.05-9.95) and 3.6 times more likely to 
have COPD than non-smokers (95% CI 3.11-4.07). 
 
 
Figure 4-13 Percent of smoker and non-smoker STEMI patients in Florida 
during 2006-2007 who received interventions. 
 
Alcohol abusers were 0.5 times less likely to be hypertensive than non-
alcohol drinkers (95% CI 0.28-0.89) and were more likely to be early seniors 
(68.9% n=31). All other associations with alcohol abuse were not statistically 
significant. 
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4.3.6 Congestive Heart Failure 
Almost 30% (n=2480) of the cohort had congestive heart failure; most of 
these were in the mid-senior category (41.3% n=1025). Compared to 
patients without CHF, these patients were less likely to receive diagnostic 
cardiac catheterization (OR 0.46, 95% CI 0.41-0.51) or receive PCI (OR 0.38 
95% CI 0.34-0.42), but were more likely to have CABG (OR 1.58, 95% CI 
1.35-1.84). Ten percent of those with CHF had dementia (OR 1.73, 95% CI 
1.46-2.05) and were 1.5 times more likely to have Alzheimer‟s (95% CI 
1.11-1.98). Over 7% of CHF patients had strokes or had history of a stroke 
(OR 1.98, 95% CI 1.62-2.42) and more than a third were diabetic (35.5% 
n=2480) (OR 1.54, 95% CI 1.4-1.7).  
 
CHF patients were 0.7 times less likely to be hyperlipidemic (95% CI 0.66-
0.80) or smokers (95% CI 0.60-0.81) than non-CHF patients, but were 1.5 
times more likely to be depressed (95% CI 1.27-1.87). Almost a third of CHF 
patients suffered from COPD, 31.8% (OR 2.32, 95% CI 2.08-2.59); they 
were 2.9 times more likely to have early stage renal disease (95% CI 2.04-
4.24) and 3.3 times more likely to have chronic kidney disease (95% CI 2.9-
3.7) than non-CHF patients. 
 
4.3.7 End Stage Renal Disease and Chronic Kidney Disease 
Only 1.4% (n=118) of the total cohort and 1.6% (n=10) of those with 
dementia had a diagnosis of end stage renal disease (ESRD), but of those 
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diagnosed with ESRD, 8.5% had dementia (Figure 4-14) and 2.5% were 
diagnosed with Alzheimer‟s.  Patients with ESRD were less likely to receive 
diagnostic cardiac catheterization (OR 0.49, 95%CI 0.34, 0.71) or PCI (OR 
0.59, 95% CI 0.41, 0.86) than those without it and 6% of the patients with 
ESRD received CABG (OR 0.6096, 95% CI 0.28, 1.31).  
 
Most of the ESRD patients were in the early senior group (49.1%) and were 
white non-Hispanic (69.49%).  ESRD patients were 3.6 times more likely to 
have hypertension (95% CI 2.05, 6.28), 2.8 times more likely to have 
diabetes (95% CI 1.97, 4.09) and 2.9 times more likely to have CHF (95% CI 
2.04, 4.24) than patients without ESRD; however they were 0.4 times less 
likely to have hyperlipidemia (95% CI 0.30, 0.64). 
 
 
*ESRD (End Stage Renal Disease), CKD (Chronic Kidney Disease). 
 
Figure 4-14 Prevalence of dementia among STEMI patients with ESRD* and 
CKD* who received interventions.  
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Fourteen percent (n=1198) of the cohort had CKD. Patients with CKD were 
less likely to receive diagnostic cardiac catheterization (OR 0.44 95% CI 
0.38, 0.50) and PCI (OR 0.45, 95% CI 0.40, 0.51) but were 1.3 times more 
likely to go through CABG (95% CI 1.04, 1.55) than those without CKD. Most 
were males (61.5%), mid-seniors (40.6%) and White-non Hispanic (79%). 
Those diagnosed with CKD were 1.7 times more likely to have a diagnosis of 
dementia (95% CI 1.36, 2.05) and 1.9 times more Alzheimer‟s (95% CI 
1.35, 2.63) than those without CKD (Figure 4-14). 
 
Patients with CKD were 1.8 times more likely to have had strokes or a 
current stroke (95% CI 1.41, 2.29), more likely to be hypertensive (OR 2.8, 
95% CI 2.38, 3.29), diabetic (OR 2.07 95%CI 1.83, 2.35), 1.5 times more 
likely to have COPD (95% CI 1.28, 1.70) and 3.3 times more likely to have 
CHF (95% CI 2.91, 3.74) than patients without CKD. Those with CKD were 
0.9 times less likely to have hyperlipidemia (95% CI 0.76, 0.97) and 0.5 
times less likely to be smokers (95% CI 0.44, 0.68). 
 
Patients with CKD were 16.6% more hyperlipidemic (53.0% vs.36.4%) and 
smoked 2% more than patients with ESRD (7.93% vs. 5.93%); however 
there were 10.3% more patients with ESRD that were diabetics than were 
there CKD patients with diabetes (53.4% vs. 43.1%). There were 2.1% more 
patients with ESRD that were obese than there were obese CKD patients 
(Figure 4-15). 
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* COPD (Chronic Obstructive Pulmonary Disease), DM (Diabetes), CHF (Congestive Heart Failure), HLP 
(Hyperlipidemia), HTN (Hypertension).  
 
Figure 4-15 Prevalence of common risk factors among STEMI patients with 
end stage renal disease (ESRD) or chronic kidney disease (CKD) in Florida 
during 2006-2007.  
 
4.3.8 Depression 
There were 450 patients diagnosed with depression in the cohort (5.40%) 
and most were women (64% n=288). Older seniors were less depressed 
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diagnosed depressed received cardiac catheterization (OR 0.56, 95% CI 
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and those depressed were 3.3 times more likely to have Alzheimer‟s disease 
than non-depressed patients (95% CI 2.20-4.89).  
 
Three quarters of all depressed patients were hypertensive (OR 1.47, 95% CI 
1.18-1.82), 33.3% had COPD (OR 1.9, 95% CI 1.58, 2.37) and depressed 
patients were 1.5 times more likely to have CHF than non depressed (95% CI 
1.26, 1.87). Although most had hyperlipidemia (57.3%), it was not 
statistically significant. A diagnosis of depression was 1.5 times more likely to 
be associated with CHF (95% CI 1.26-1.87) than non-depressed. 
 
4.3.9 Obesity 
Only 6.5% (n=542) of the cohort was coded obese.  Of these, 12% smoked, 
16% had CKD, 23% COPD and 28% CHF, but the associations were not 
statistically significant. However over 70% of the obese had hyperlipidemia 
(OR 1.9, 95% CI 1.58-2.31) and were 2.4 times more likely to be diabetic 
than non obese patients (95% CI 2.03-2.88). Over 80% of the obese were 
hypertensive (OR 2.02, 95% CI 1.62-2.50). 
 
4.4 Overview of Descriptive Statistics by Dementia 
The prevalence of dementia in the study was 7.3%. Most demented patients 
were White non-Hispanic but Black/African American non-Hispanics had the 
highest prevalence of dementia among all ethnic groups (11.4%). Almost 
60% of all demented were females. As expected, most demented patients 
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belonged to the 85 or older age category (48.1%). One third of demented 
patients had a diagnosis of AD.  
 
The highest percentage of demented patients arrived to the hospital in the 
afternoon hours (25.8%) while most non-demented patients arrived to the 
hospital in the morning (25.6%). Ninety four percent of demented patients 
paid through Medicare. 
 
Only 46.8% of demented patients received diagnostic cardiac catheterization, 
40% received PCI and 3.6% received CABG (refer to figure 4-5).  Only 
37.5% of demented patients received PCI within the first 24 hours after 
arrival to the hospital compared to 61.7% of non-demented who did receive 
PCI within a day; 2.6% of demented patients received CABG within the first 
24 hours while 5.6% of non-demented patients received it on the same day 
of arrival.  
 
When comorbidities were stratified by dementia status, demented patients 
were 1.55 times more likely to have or have had a stroke than non-dements 
(95% CI 1.11-2.15); over three times more likely to have depression (OR 
3.25, 95% CI 2.52-4.19); 1.67 times more likely to have chronic kidney 
disease (95% CI 1.36-2.05) and 1.7 times more likely to have congestive 
heart failure (95% CI 1.46-2.05); however demented patients were 0.56 
times less likely to have hyperlipidemia (OR 0.56, 95% CI 0.47-0.66); 0.47 
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times less likely to be obese (OR 0.47, 95% CI 0.30-0.74) and 0.33 times 
less likely to be smokers or had ever smoked (OR 0.33, 95% CI 0.23-0.49).  
 
There were no statistically significant differences between demented and no 
demented patients in regards to hypertension (OR 0.9, 95% CI 0.76-1.08), 
diabetes (OR 0.92, 95% CI 0.76-1.10), ESRD (OR 1.2, 95% CI 0.62-2.27), 
alcohol abuse (OR 0.9, 95% CI 0.28-2.95) or COPD (OR 1.06, 95% CI 0.87-
1.30). Refer to figure 4-16 for details of comorbidity for dementia patients. 
 
 
 
*ESRD (End Stage Renal Disease), DEP (Depression), CKD (Chronic Kidney Disease), DM (Diabetes), CHF 
(Congestive Heart Failure), HLP (Hyperlipidemia), HTN (hypertension). 
 
Figure 4-16 Prevalence of common risk factors for STEMI patients by 
dementia status.  
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4.5 Overview of Descriptive Statistics by Gender 
Most of the cohort consisted of men, 56.7% (n=4726), yet most dements 
were women (60%, n=362) and 1.2% more women than men had an 
Alzheimer‟s diagnosis, 3.05% vs. 1.86% (OR 0.60, 95% CI 0.45-0.80).  
Males were 1.9 times more likely than women to receive cardiac 
catheterization (95% CI 1.69-2.08); 1.4 times more likely to be given PCI 
(95% CI 1.27-1.53) and 2.2 times more likely to go through CABG (95% CI 
1.89-2.64) (Figure 4-6). 
 
Most men were in the early senior category and most women were in the mid 
senior years, 54% and 40% respectively (Figure 4-17).  Most white non-
Hispanic and Hispanics were males (56.4% and 61.8%), while most Black 
non-Hispanics/African Americans were women (50.4%). 
 
 
Figure 4-17 Age Distribution of STEMI Patients by Gender. 
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 Males were less likely to have strokes (OR 0.72, 95% CI 0.59-0.88), 
hypertension (OR 0.75, 95% CI 0.68-0.83), depression (OR 0.41, 95% CI 
0.33-0.50), CHF (OR 0.72, 95% CI 0.66-0.79)  and COPD (OR 0.86, 95% CI 
0.77-0.96) than women (Figure 4-18); but they were more likely to have 
hyperlipidemia (OR 1.12, 95% CI 1.02-1.22) and chronic kidney disease (OR 
1.26, 95%CI 1.11-1.43). Males were 4.2 times more likely to drink alcohol 
than females (95% CI 1.86-9.34) and 1.3 times more likely to be smokers or 
have a history of smoking (95% CI 1.45-1.49).  
 
 
4.6 Multivariate Logistic Regression Analysis 
4.6.1 Main Research Question 
 
To address the main research question evaluating if there is a disparity in the 
use of cardiac catheterization for ST-Myocardial Infarction patients with a 
diagnosis of dementia versus patients without a diagnosis of dementia after 
controlling for the following patient and hospital factors: age; gender; 
ethnicity; zip code SES; year of hospital admission; hour of arrival at the 
emergency department; source of admission; principal payer and the 
following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), 
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), 
depression (DEP), end stage renal disease (ESRD), chronic kidney disease 
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD) and chronic alcohol abuse (OH), models one, two and three were run 
(Table 4-6). 
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Model one addressed the probability of receiving diagnostic cardiac 
catheterization among STEMI patients with and without dementia, not 
adjusting for any other variables. A total of 8,331 observations were read; of 
these 6,435 received diagnostic cardiac catheterization. Patients with a 
diagnosis of dementia were less likely to receive catheterizations than 
patients without dementia (OR 0.22; 95% CI 0.19-0.27, p<0.0001).  
 
 
Only 93.5% (n=7791) of the cohort had Florida zip code data and 
consequently had the proxy for zip code socio-economic status (SES). From 
the available zip code SES data, the mean income of the cohort was 
$35,086.30 (95% CI $30,865.5 - $39,307.0 p<0.0001). Demented patients 
reported less income than non-demented ($29,471.40 vs. $35,532.30). 
 
Model two adjusted for all variables of interest. There were 7,791 
observations read and of these 5,985 received diagnostic cardiac 
catheterization. After adjusting for all covariates, patients with dementia 
were less likely to receive catheterizations than patients without dementia 
(OR 0.41, 95% CI 0.34, 0.50; p<0.0001). 
 
Model three did not adjust for zip code SES to see if there was a difference in 
reducing the cohort by 540 observations and/or adjusting for this variable; 
there were 8,331 observations read and 6,435 of these received cardiac 
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catheterization. The only affected variable by excluding zip code SES from 
model two was diabetes, which became statistically significant (OR 0.87; 
95% CI 0.77-0.99; p=0.0324); all other variables remain unaffected. 
 
Overall non-demented patients were 2.4 times more likely to receive 
diagnostic cardiac catheterization than demented patients. Other conditions 
that reduced the odds of receiving cardiac catheterization were: being 
female; Black non-Hispanic ethnicity; having a stroke or having history of a 
stroke; diagnosis of depression, CKD, CHF, or COPD. In addition, if a patient 
was younger, had cardiovascular risk factors of hyperlipidemia, obesity and 
was a current smoker, they were more likely to receive diagnostic cardiac 
catheterization than if they did not. However, having hypertension and 
drinking alcohol did not impact the outcome, nor did zip code SES, year of 
admission, hour of arrival, source of admission to the hospital, method of 
payment used, or having ESRD. 
 
 
  
  
93 
 
Table 4-6 Results of Multivariate Logistic Regression for main research 
question modeling the probability of diagnostic cardiac catheterization.  
 
 Model One 
(n=8331) 
Odds Ratio (95% CI) 
Diagnostic Cardiac 
Catheterization as 
Outcome 
Model Two 
(n=7791) 
Odds Ratio (95% CI) 
Diagnostic Cardiac 
Catheterization as 
Outcome  
Model Three 
(n=8831) 
Odds Ratio (95% CI) 
Diagnostic Cardiac 
Catheterization as 
Outcome 
Dementia 0.22 (0.19-0.27) 0.41 (0.34-0.50) 0.41 (0.34-0.50) 
Age Category 
65-74  
75-84 
85+  
  
3.90 (3.31-4.58) 
3.00 (2.59-3.48) 
1.00 
 
3.98 (3.40-4.66) 
2.99 (2.59-3.45) 
1.00 
Gender 
Female 
Male 
  
0.69 (0.61-0.77) 
1.00 
 
0.70 (0.62-0.78) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
  
1.00 
0.55 (0.43-0.71) 
1.06 (0.88-1.28) 
 
1.00 
0.57 (0.44-0.73) 
1.06 (0.89-1.04) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
  
1.02 (0.87-1.21) 
0.91 (0.78-1.05) 
1.00 
 
 
Year 
2006 
2007 
  
0.94 (0.84-1.05) 
1.00 
 
0.93 (0.83-1.04) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
  
0.83 (0.69-1.00) 
1.00 
0.91 (0.77-1.08) 
0.78 (0.66-0.93) 
0.82 (0.59-1.15) 
 
0.85 (0.71-1.02) 
1.00 
0.92 (0.78-1.08) 
0.77 (0.66-0.91) 
0.81 (0.59-1.11) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
  
1.08 (0.53-2.22) 
0.99 (0.50-1.96) 
1.00 
 
1.16 (0.59-2.30) 
1.04 (0.54-2.01) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
  
1.21 (0.97-1.50) 
1.13 (0.60-2.12) 
1.00 
 
1.18 (0.96-1.45) 
0.97 (0.56-1.71) 
1.00 
Hypertension  1.02 (0.89-1.16) 0.99 (0.87-1.12) 
Diabetes Type 2  0.90 (0.79-1.03) 0.87 (0.77-0.99) 
Stroke  0.61 (0.48-0.77) 0.59 (0.47-0.75) 
Hyperlipidemia  1.51 (1.34-1.70) 1.51 (1.35-1.70) 
Obesity  1.51 (1.15-1.99) 1.50 (1.15-1.95) 
Smoking  1.70 (1.38-2.11) 1.79 (1.45-2.21) 
Depression  0.71 (0.56-0.89) 0.72 (0.57-0.90) 
End Stage Renal Disease  0.87 (0.56-1.33) 0.86 (0.57-1.31) 
Chronic Kidney Disease  0.61 (0.52-0.71) 0.62 (0.53-0.72) 
Congestive Heart Failure  0.64 (0.57-0.73) 0.67 (0.59-0.75) 
COPD  0.71 (0.62-0.82) 0.70 (0.61-0.80) 
Chronic Alcohol abuse  1.14 (0.46-2.81) 1.03 (0.44-2.40) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) 
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4.6.2 Secondary Research Questions 
 
4.6.2.1 Secondary Question #1 
Models four, five and six were run to determine if there was a difference in 
PCI use between STEMI patients with and without dementia who underwent 
cardiac catheterization compared to those who did not receive PCI but did 
receive diagnostic cardiac catheterization. Only PCI was measured as 
outcome for models 4 to 6; the models do not include patients who received 
CABG. Model four was run without adjusting for any covariates, model five 
adjusted for all covariates and model six adjusted for all covariates except 
SES (Table 4-7). 
 
After diagnostic cardiac catheterization, females were 1.4 times more likely 
to receive PCI than males (95% CI 1.21-1.69; p <0.0001). Those patients 
that belonged to a Florida zip code in which the average per capita income 
was estimated to be less than $7,750 were 1.4 times more likely to receive 
PCI. Also those with ESRD were more likely to undergo PCI (OR 2.66; 95% 
CI 1.17-6.04). Patients who were diabetics, had strokes, presented CHF and 
COPD were less likely to receive PCI. When the proxy for zip code SES was 
eliminated for model six, ESRD was no longer statistically significant (OR 
2.07; 95% CI 0.99-4.34; p=0531); nevertheless all other significant 
variables in model five were still significant in model six. 
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Table 4-7 Results of Multivariate Logistic Regression for secondary research 
question #2 modeling the probability of receiving PCI for those patients that 
received diagnostic cardiac catheterization.  
 
 Model Four  
(n=6435) 
Odds Ratio (95% CI) 
PCI as Outcome for 
those who receive 
catheterization 
Model Five 
(n=5985) 
Odds Ratio (95% CI) 
PCI as Outcome for 
those who receive 
catheterization 
Model Six 
(n=6435) 
Odds Ratio (95% CI) 
PCI as Outcome for 
those who receive 
catheterization 
Dementia 0.88 (0.63-1.24) 0.92 (0.64-1.32) 0.92 (0.64-1.31) 
Age Category 
65-74  
75-84 
85+  
  
0.66 (0.49-0.89) 
0.61 (0.45-0.81) 
1.00 
 
0.65 (0.49-0.87) 
0.59 (0.44-0.78) 
1.00 
Gender 
Female 
Male 
  
1.43 (1.21-1.69) 
1.00 
 
1.48 (1.26-1.74) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
  
1.00 
0.96 (0.65-1.43) 
0.92 (0.73-1.17) 
 
1.00 
0.98 (0.67-1.43) 
1.00 (0.80-1.25) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
  
1.38 (1.10-1.74) 
1.01 (0.83-1.23) 
1.00 
 
 
Year 
2006 
2007 
  
0.99 (0.84-1.16) 
1.00 
 
0.97 (0.84-1.13) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
  
0.99 (0.77-1.28) 
1.00 
1.03 (0.83-1.30) 
1.06 (0.84-1.35) 
0.94 (0.60-1.46) 
 
1.0 (0.78-1.28) 
1.00 
1.02 (0.82-1.27) 
1.07 (0.85-1.34) 
0.97 (0.64-1.48) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
  
0.38 (0.11-1.33) 
0.48 (0.15-1.60) 
1.00 
 
0.33 (0.09-1.12) 
0.46 (0.14-1.51) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
  
0.997 (0.75-1.33) 
0.95 (0.45-2.00) 
1.00 
 
1.0 (0.77-1.31) 
0.99 (0.50-1.96) 
1.00 
Hypertension  0.93 (0.78-1.13) 0.93 (0.79-1.10) 
Diabetes Type 2  0.70 (0.59-0.83) 0.72 (0.61-0.85) 
Stroke  0.53 (0.38-0.72) 0.54 (0.40-0.74) 
Hyperlipidemia  1.16 (0.99-1.37) 1.18 (1.01-1.37) 
Obesity  0.82 (0.62-1.08) 0.78 (0.59-1.01) 
Smoking  1.28 (1.00-1.63) 1.23 (0.97-1.54) 
Depression  0.78 (0.56-1.08) 0.77 (0.56-1.06) 
End Stage Renal Disease  2.66 (1.17-6.04) 2.07 (0.99-4.34) 
Chronic Kidney Disease  0.81 (0.64-1.02) 0.83 (0.67-1.04) 
Congestive Heart Failure  0.39 (0.33-0.47) 0.38 (0.33-0.45) 
COPD  0.69 (0.57-0.83) 0.69 (0.57-0.82) 
Chronic Alcohol abuse  1.16 (0.43-3.12) 1.26 (0.47-3.37) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) 
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4.6.2.2 Secondary Question #2 
Models seven, eight and nine run to ascertain if there was a disparity of 
CABG use between STEMI patients with and without dementia who 
underwent cardiac catheterization compared to those who did not receive 
CABG but did receive diagnostic cardiac catheterization (Table 4-8). 
 
Model seven did not adjust for any covariates; model eight adjusted for all 
covariates and model nine adjusted for all covariates except zip code SES; 
but this did not produce any statistically significant change. Overall younger 
patients are more likely to undergo CABG than older patients as well as 
patients with diabetes, strokes, obesity, CKD, CHF and COPD. On the other 
hand females, those in the lower SES and with end stage renal disease, were 
less likely to undergo CABG than those patients that were males and did not 
have the mentioned comorbidities. For complete results see table 4-8.  
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Table 4-8 Results of Multivariate Logistic Regression for secondary research 
question #3 modeling the probability of receiving CABG for those patients 
that received diagnostic cardiac catheterization.  
 
 Model Seven 
(n=6435) 
Odds Ratio (95% CI) 
CABG as Outcome  
for those who receive 
catheterization 
Model Eight 
(n=5985) 
Odds Ratio (95% CI) 
CABG as Outcome 
for those who receive 
catheterization  
Model Nine 
(n=6435) 
Odds Ratio (95% CI) 
CABG as Outcome 
for those who receive 
catheterization 
Dementia 0.64 (0.41-0.99) 0.74 (0.46-1.20) 0.74 (0.47-1.17) 
Age Category 
65-74  
75-84 
85+  
 
 
 
3.21 (2.14-4.82) 
2.83 (1.89-4.23) 
1.00 
 
3.18 (2.15-4.70) 
2.85 (1.93-4.20) 
1.00 
Gender 
Female 
Male 
  
0.52 (0.43-0.63) 
1.00 
 
0.52 (0.43-0.62) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
  
1.00 
0.85 (0.55-1.32) 
1.05 (0.81-1.36) 
 
1.00 
0.87 (0.58-1.32) 
0.96 (0.75-1.21) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
  
0.59 (0.46-00.75) 
0.92 (0.75-1.13) 
1.00 
 
 
 
 
Year 
2006 
2007 
  
0.95 (0.80-1.12) 
1.00 
 
0.92 (0.79-1.08) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
  
1.01 (0.77-1.31) 
1.00 
0.96 (0.76-1.21) 
0.74 (0.57-0.96) 
1.20 (0.75-1.92) 
 
1.00 (0.77-1.92) 
1.00 
0.98 (0.79-1.22) 
0.74 (0.58-0.95) 
1.11 (0.71-1.73) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
  
1.42 (0.47-4.34) 
1.45 (0.51-4.17) 
1.00 
 
1.74 (0.58-5.22) 
1.49 (0.52-4.23) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
  
0.93 (0.70-1.24) 
1.22 (0.59-2.50) 
1.00 
 
0.91 (0.70-1.19) 
0.98 (0.50-1.93) 
1.00 
Hypertension  1.05 (0.87-1.26) 1.02 (0.86-1.22) 
Diabetes Type 2  1.32 (1.10-1.58) 1.28 (1.08-1.52) 
Stroke  1.88 (1.33-2.65) 1.79 (1.29-2.49) 
Hyperlipidemia  0.92 (0.77-1.10) 0.89 (0.75-1.04) 
Obesity  1.51 (1.15-1.99) 1.50 (1.15-1.96) 
Smoking  0.91 (0.71-1.16) 0.94 (0.75-1.18) 
Depression  1.16 (0.79-1.68) 1.18 (0.83-1.69) 
End Stage Renal Disease  0.37 (0.15-0.90) 0.34 (0.14-0.82) 
Chronic Kidney Disease  1.42 (1.11-1.82) 1.46 (1.16-1.84) 
Congestive Heart Failure  1.96 (1.63-2.36) 1.97 (1.66-2.34) 
COPD  1.39 (1.13-1.69) 1.38 (1.14-1.67) 
Chronic Alcohol abuse  1.06 (0.42-2.67) 0.99 (0.40-2.45) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) 
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4.6.2.3 Secondary Question #3 
Models ten through fifteen were run to determine if there was a difference 
between the days to procedure (PCI or CABG) for STEMI patients with and 
without dementia (Tables 4-9, 4-10) 
  
Models 10-12 evaluated same day PCI. Model 10 calculated the probability of 
same day PCI for STEMI patients with and without dementia. Model 11 
assessed the probability of same day PCI for those patients that received 
diagnostic cardiac catheterization with and without dementia. Model 12 is 
based on model ten but adjusts for all covariates of interest.  
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Table 4-9 Results of Multivariate Logistic Regression models for secondary 
research question #3 modeling the probability of same day PCI for STEMI 
patients. 
 
 Model ten 
(n=7791) 
Odds Ratio (95% CI) 
Same day PCI as 
Outcome 
Model Eleven 
(n=6435) 
Odds Ratio (95% CI) 
Same day PCI as 
Outcome for those who 
receive catheterization  
Model Twelve 
(n=7791) 
Odds Ratio (95% CI) 
Same day PCI as 
Outcome 
Dementia 0.34 (0.29-0.41) 0.93 (0.71-1.24) 0.53 (0.44-0.64) 
Age Category 
65-74  
75-84 
85+  
   
2.25 (1.94-2.61) 
1.87 (1.63-2.15) 
1.00 
Gender 
Female 
Male 
   
0.97 (0.88-1.07) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
   
1.00 
0.66 (0.53-0.83) 
0.98 (0.84-1.15) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
   
1.11 (0.96-1.28) 
0.95 (0.84-1.07) 
Year 
2006 
2007 
   
0.89 (0.81-0.99) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
   
0.85 (0.73-1.00) 
1.00 
0.95 (0.83-1.09) 
0.79 (0.68-0.91) 
0.83 (0.63-1.10) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
   
1.09 (0.60-1.98) 
1.08 (0.61-1.89) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
   
1.03 (0.86-1.23) 
1.03 (0.62-1.70) 
1.00 
Hypertension   0.94 (0.84-1.05) 
Diabetes Type 2   0.74 (0.66-0.83) 
Stroke   0.54 (0.43-0.68) 
Hyperlipidemia   1.30 (1.18-1.44) 
Obesity   1.05 (0.86-1.29) 
Smoking   1.55 (1.32-1.82) 
Depression   0.70 (0.57-0.87) 
End Stage Renal Disease   1.39 (0.92-2.08) 
Chronic Kidney Disease   0.60 (0.52-0.69) 
Congestive Heart Failure   0.48 (0.43-0.53) 
COPD   0.66 (0.59-0.75) 
Chronic Alcohol abuse   1.16 (0.59-2.30) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) 
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Overall, if a patient had dementia they were less likely to receive PCI within 
the first twenty four hours than someone who did not have dementia (OR 
0.34, 95% CI 0.29-0.41).  This was still statistically significant after adjusting 
for all covariates of interest. When potential confounders were adjusted, 
being younger, hyperlipidemic and a smoker placed the patient at better 
odds of receiving same day PCI; while if the patient was Black/African-
American non-Hispanic, hypertensive, had a stroke or had a history of 
stroke, depression, CKD, CHF and COPD they were less likely to receive same 
day PCI. Model eleven was run for those who received diagnostic cardiac 
catheterization without adjusting for any covariates, having dementia was 
not statistically significant for receiving same day PCI. 
 
To evaluate same day CABG, modes 13-15 were run. Model 13 appraised the 
probability of same day CABG for STEMI patients with and without dementia 
compared to those STEMI patients with and without dementia who did not 
receive same day CABG. Model 14 assessed the probability of same day 
CABG for those STEMI patients with and without dementia who received 
diagnostic cardiac catheterization compared to those STEMI patients with and 
without dementia who did not receive same day CABG  and model 15 is 
based on model thirteen but adjusts for all covariates of interest; refer to 
table 4-10. 
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Table 4-10 Results of Multivariate Logistic Regression models for secondary 
research question #3 modeling the probability of same day CABG for STEMI 
patients. 
 
 Model thirteen 
(n=7791) 
Odds Ratio (95% CI) 
Same day CABG as 
Outcome 
Model fourteen 
(n=6435) 
Odds Ratio (95% CI) 
Same day CABG as 
Outcome for those who 
receive catheterization  
Model fifteen 
(n=7791) 
Odds Ratio (95% CI) 
Same day CABG as 
Outcome 
Dementia 0.45 (0.27-0.76) 0.871 (0.52-1.46) 0.69 (0.40-1.18) 
Age Category 
65-74  
75-84 
85+  
   
3.50 (2.21-5.51) 
2.94 (1.18-4.62) 
1.00 
Gender 
Female 
Male 
   
0.50 (0.39-0.63) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
   
1.00 
0.82 (0.48-1.41) 
1.17 (0.86-1.59) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
   
0.80 (0.59-1.07) 
0.96 (0.74-1.24) 
1.00 
Year 
2006 
2007 
   
1.05 (0.86-1.29) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
   
0.74 (0.53-1.03) 
1.00 
0.90 (0.69-1.19) 
0.52 (0.37-0.73) 
0.73 (0.41-1.27) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
   
1.33 (0.38-4.63) 
0.86 (0.26-2.83) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
   
1.13 (0.78-1.62) 
1.27 (0.51-3.15) 
1.00 
Hypertension   1.01 (0.81-1.27) 
Diabetes Type 2   0.98 (0.78-1.23) 
Stroke   1.60 (1.06-2.41) 
Hyperlipidemia   0.90 (0.73-1.11) 
Obesity   1.38 (0.97-1.96) 
Smoking   0.84 (0.62-1.15) 
Depression   1.14 (0.72-1.79) 
End Stage Renal Disease   0.34 (0.08-1.44) 
Chronic Kidney Disease   0.79 (0.57-1.10) 
Congestive Heart Failure   1.49 (1.18-1.87) 
COPD   1.38 (1.08-1.75) 
Chronic Alcohol abuse   0.60 (0.14-2.56) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) 
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Patients with dementia were much less likely to receive CABG within the first 
twenty four hours than someone who did not have dementia (OR 0.45, 95% 
CI 0.27-0.76).  However when potential confounders were adjusted for this 
effect was not statistically significant. Being younger, hyperlipidemic, having 
COPD or CHF placed the patient at better odds of receiving same day CABG; 
whereas if the patient was a female or was admitted at night, versus the 
morning, they were less likely to receive same day CABG. When model 
fourteen was run for those who received diagnostic cardiac catheterization 
without adjusting for any covariates, having dementia was not statistically 
significant for receiving same day CABG. 
 
 
4.6.2.4 Secondary Question #4 
Models sixteen through nineteen were constructed to identify if having 
dementia affected the length of hospital stay for STEMI patients (Table 4-
11). 
 
To best evaluate this time-dependent variable a Cox regression analysis was 
conducted only on STEMI patients with and without dementia who survived 
the hospital stay. Although Cox regression assumes that the hazards of the 
comparison groups are proportional, this model fits the data better than a 
logistic regression model. Model sixteen is unadjusted, model seventeen 
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adjusts for all covariates of interest and model eighteen adjusts for all 
variables except zip code SES. 
 
In model 16, the hazard ratio assumed that the exposure of STEMI patients 
to length of hospital stay is multiplicative of some underlying hazard, in this 
case dementia. The result showed that patients with dementia had longer 
length of hospital stay than patients without dementia (hazard ratio=0.90, 
p=0.0203).  When all covariates of interest where added in model seventeen, 
the predictability of dementia became statistically insignificant (hazard 
ratio=1.0, p=0.9667) indicating that one of the covariates was highly 
correlated with the dementia factor. However when the correlations were 
analyzed in the basic model 2, there were no strong correlations of any one 
variable with dementia.  
 
After adjusting for all variables of interest in model 17, patients 75-84 years 
of age and Black/African American non-Hispanics had a significantly lower 
hazard of being released from the hospital on any day of their stay than 
those patients without dementia (Table 4-11); also those who arrived at 
night had significantly lower hazard of being discharged (hazard ratio=0.928, 
p=0.0352) compared to those that arrived in the morning hours.  
Comorbidities such as diabetes, current or history of stroke, hyperlipidemia, 
obesity, smoking, depression, chronic kidney disease, congestive heart 
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failure, chronic obstructive pulmonary disease and chronic alcohol abusers 
also had lower hazard of being released from the hospital than those without 
those conditions. However, patients with hyperlipidemia and current or 
history of smoking had significantly higher hazard of being discharged from 
the hospital than those without hyperlipidemia or positive smoking status. 
When model eighteen was run without adjusting for SES, there were no 
changes from model seventeen indicating that SES was not a confounder on 
the previously stated associations. 
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Table 4-11 Results of Cox regression analysis for secondary research 
question #4 modeling length of hospital stay for STEMI patients. 
 
 Model sixteen 
(n=7422) 
Hazard Ratio (p) 
for STEMI survivors 
Model seventeen 
(n=7422) 
Hazard Ratio (p) 
for STEMI survivors 
Model eighteen 
(n=7422) 
Hazard Ratio (p) 
for STEMI survivors 
Dementia 0.898 (p=0.0203) 0.998 (p=0.9667) 1.002 (p=0.9608) 
Age Category 
65-74  
75-84 
85+  
  
1.002(p=0.9601) 
0.914 (p=0.0147) 
1.00 
 
0.994 (p=0.8784) 
0.905 (p=0.0054) 
1.00 
Gender 
Female 
Male 
  
0.993 (p=0.7672) 
1.00 
 
0.996 (p=0.8688) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
  
1.00 
0.877 (p=0.0229) 
1.028 p=(0.4718) 
 
1.00 
0.873 (p=0.0161) 
1.026 (p=0.4906) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
  
1.016 (p=0.6502) 
1.036 (p=0.2566) 
1.00 
 
 
 
Year 
2006 
2007 
  
0.995 (p=0.8211) 
1.00 
 
0.997 (p=0.8905) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
  
1.007 (p=0.8524) 
1.00 
0.991 (p=0.7839) 
0.928 (p=0.0352) 
1.018 (p=0.8092 
 
1.007 (p=0.8555) 
1.00 
0.986 (p=0.6784) 
0.931 (p=0.0391) 
1.054 (p=0.4424) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
  
0.993 (p=0.9666) 
1.029 (p=0.8426) 
1.00 
 
0.934 (p=0.6514) 
1.028 (p=0.8424) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
  
0.967 (p=0.4455) 
0.818(p=0.1043) 
1.00 
 
0.989 (p=0.7916) 
0.860 (p=0.1818) 
1.00 
Hypertension  0.973 (p=0.3110) 0.986 (p=0.6015) 
Diabetes Type 2  0.914 (p=0.0012) 0.916 (p=0.0011) 
Stroke  0.683 (p<0.0001) 0.681 (p<0.0001) 
Hyperlipidemia  1.122 (p<0.0001) 1.125 (p<0.0001) 
Obesity  0.894 (p=0.0201) 0.901 (p=0.0277) 
Smoking  1.110 (p=0.0054) 1.104 (p=0.0060) 
Depression  0.843 (p=0.0012) 0.840 (p=0.0007) 
End Stage Renal Disease  0.841 (p=0.1413) 0.834 (p=0.1186) 
Chronic Kidney Disease  0.728 (p<0.0001) 0.717 (p<0.0001) 
Congestive Heart Failure  0.509 (p<0.0001) 0.506 (p<0.0001) 
COPD  0.809 (p<0.0001) 0.806 (p<0.0001) 
Chronic Alcohol abuse  0.697 (p=0.0242) 0.712 (p=0.0280) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) 
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4.7 Sensitivity Analysis 
 
A sensitivity analysis was carried out to determine if it is appropriate or not 
to use the broad definition of dementia compared to the strict or more 
specific definition of Alzheimer‟s disease. Table 4-12 compares the three 
models used. All models are based on 7,791 observations with proxy data for 
SES modeling the probability of receiving diagnostic cardiac catheterization. 
 
General model two was used as the comparison since it used the broad 
definition of dementia. Model 19 used the same 7,991 observations as model 
two but the definition of dementia was restricted to only those that had 
dementia type Alzheimer‟s and model 20 looked at those patients that had 
dementia but not a diagnosis of Alzheimer‟s disease. 
 
The results obtained from all three models (refer to table 4-12) showed that 
there were no statistically significant differences between using the broad 
definition of dementia compared to the more strict definition of Alzheimer‟s 
disease when testing diagnostic cardiac catheterization as the outcome. 
However when exposure is limited only to those patients with Alzheimer‟s 
diagnosis, the effect of dementia is slightly stronger (OR 0.38, 95% CI 0.28-
0.52) compared to the effect for all demented patients (OR 0.41, 95% CI 
0.34-0.50). 
  
  
107 
 
Table 4-12 Results of sensitivity analysis evaluating the broad definition of 
dementia versus the definition of Alzheimer‟s disease. 
 
 Model two 
(n=7791) 
Odds Ratio (95% CI) 
Diagnostic Cardiac 
Catheterization as 
Outcome Where 
Exposure is 
Dementia◊  
Model Nineteen 
 (n=7791) 
Odds Ratio (95% CI) 
Diagnostic Cardiac 
Catheterization as 
Outcome Where 
Exposure Dementia  
AD◊ 
Model twenty 
(n=7791) 
Odds Ratio (95% CI) 
Diagnostic Cardiac 
Catheterization as 
Outcome Where 
Exposure is  
Dementia non-AD◊ 
Dementia 0.41 (0.34-0.50) 0.38 (0.28-0.52) 0.44 (0.35-0.56) 
Age Category 
65-74  
75-84 
85+  
 
3.90 (3.31-4.58) 
3.00 (2.59-3.48) 
1.00 
 
4.30 (3.67-5.04) 
3.20 (2.77-3.70) 
1.00 
 
3.81 (3.23-4.49) 
2.96 (2.55-3.44) 
1.00 
Gender 
Female 
Male 
 
0.69 (0.61-0.77) 
1.00 
 
0.68 (0.60-0.76) 
1.00 
 
0.67 (0.59-0.76) 
1.00 
Ethnicity 
White non-Hispanic 
Black non-Hispanic 
Hispanic/Other 
 
1.00 
0.55 (0.43-0.71) 
1.06 (0.88-1.28) 
 
1.00 
0.54 (0.42-0.69) 
1.07 (0.88-1.29) 
 
1.00 
0.55 (0.43-0.71) 
1.08 (0.89-1.31) 
Zip code SES* 
< $7750 
≥$7750 <$30650 
≥$30650 
 
1.02 (0.87-1.21) 
0.91 (0.78-1.05) 
1.00 
 
1.00 (0.85-1.18) 
0.89 (0.77-1.03) 
1.00 
 
1.02 (0.86-1.21) 
0.92 (0.79-1.07) 
1.00 
Year 
2006 
2007 
 
0.94 (0.84-1.05) 
1.00 
 
0.95 (0.84-1.06) 
1.00 
 
0.95 (0.84-1.07) 
1.00 
Hour of arrival to hospital 
Early Morning 
Morning 
Afternoon 
Night 
Unknown 
 
0.83 (0.69-1.00) 
1.00 
0.91 (0.77-1.08) 
0.78 (0.66-0.93) 
0.82 (0.59-1.15) 
 
0.82 (0.68-0.99) 
1.00 
0.90 (0.77-1.07) 
0.79 (0.67-0.93) 
0.82 (0.59-1.14) 
 
0.83 (0.68-1.00) 
1.00 
0.93 (0.78-1.09) 
0.80 (0.67-0.95) 
0.81 (0.58-1.13) 
Source of Admission 
Outside Hospital MD Ref 
Emergency Room MD Ref 
Other** 
 
1.08 (0.53-2.22) 
0.99 (0.50-1.96) 
1.00 
 
1.11 (0.54-2.25) 
0.98 (0.50-1.93) 
1.00 
 
1.04 (0.49-2.21) 
0.94 (0.46-1.92) 
1.00 
Pay 
Medicare 
Self-Pay & Charity 
Other*** 
 
1.21 (0.97-1.50) 
1.13 (0.60-2.12) 
1.00 
 
1.20 (0.97-1.50) 
1.14 (0.61-2.14) 
1.00 
 
1.20 (0.96-1.49) 
1.16 (0.61-2.21) 
1.00 
Hypertension 1.02 (0.89-1.16) 1.03 (0.90-1.17) 1.01 (0.88-1.15) 
Diabetes Type 2 0.90 (0.79-1.03) 0.90 (0.79-1.02) 0.89 (0.78-1.02) 
Stroke 0.61 (0.48-0.77) 0.60 (0.47-0.76) 0.60 (0.47-0.77) 
Hyperlipidemia 1.51 (1.34-1.70) 1.52 (1.35-1.70) 1.47 (1.30-1.65) 
Obesity 1.51 (1.15-1.99) 1.52 (1.16-2.00) 1.57 (1.18-2.07) 
Smoking 1.70 (1.38-2.11) 1.72 (1.39-2.12) 1.73 (1.39-2.14) 
Depression 0.71 (0.56-0.89) 0.67 (0.53-0.84) 0.72 (0.57-0.92) 
End Stage Renal Disease 0.87 (0.56-1.33) 0.87 (0.56-1.33) 0.86 (0.56-1.32) 
Chronic Kidney Disease 0.61 (0.52-0.71) 0.61 (0.52-0.72) 0.60 (0.51-0.70) 
Congestive Heart Failure 0.64 (0.57-0.73) 0.64 (0.57-0.72) 0.64 (0.57-0.73) 
COPD 0.71 (0.62-0.82) 0.70 (0.61-0.81) 0.69 (0.60-0.79) 
Chronic Alcohol abuse 1.14 (0.46-2.81) 1.14 (0.46-2.80) 1.62 (0.56-4.71) 
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement; 
information not available) ***Other (any other method of payment: Medicaid,commercial insurance; 
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) ◊Model 2 had 591 
patients with dementia; model 19 had 190 AD patients, and model 20 had 401 dementia non-AD patients. 
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CHAPTER 5 
DISCUSSION 
5.1 Findings  
Results obtained indicate that demented STEMI patients are less likely to 
receive diagnostic cardiovascular catheterizations than non-demented 
patients, even after controlling for potential confounding factors. This finding 
is consistent with that from Sloan et al. (2004)(78). Results from this study 
indicate that demented patients are 0.4 times less likely to receive diagnostic 
cardiac catheterization than non demented patients while Sloan et al. 
(2004)(78) estimated the risk ratio at 0.5. The 95% confidence intervals for 
both studies overlapped (0.34-0.50 vs. 0.47-0.55).  
 
Models two and three also showed that being female or Black/African 
American non-Hispanic reduced the odds of receiving diagnostic cardiac 
catheterization compared to males and those White-non-Hispanic; the AHA 
and many studies in the literature support this result(3, 7, 66, 83).  
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Black African American non-Hispanics were 0.5 times less likely to receive 
diagnostic cardiac catheterization than White non-Hispanics.  Yet, the odds of 
receiving PCI or CABG for those Black African American non-Hispanics that 
did receive diagnostic cardiac catheterization became statistically insignificant 
once patient and hospital factors were taking into account. Nonetheless, 
when measuring the probability of receiving same day PCI, Blacks were 0.7 
times less likely to have same day PCI than Whites. Similar results were 
obtained in earlier analysis done by Pathak and Strom (2008)(66). 
 
Arriving to the hospital at night also seems to place patients at worse odds of 
receiving diagnostic cardiac catheterization. The analysis also suggests that 
being admitted to the hospital at night places patients at worse odds to 
receive treatment (PCI or CABG) within the first 24 hours than those who 
arrived in the morning. Arriving at night was also associated with having 
longer hospital stay than patients who arrived in the morning. Studies show 
that arriving at night or off-hours are associated with higher in patient 
mortality and longer time to treatment(84) . 
 
When the socio-economic variable was not accounted for while evaluating the 
use of diagnostic cardiac catheterizations among STEMI patients, the only 
variable affected was diabetes; however the effect was marginal given that 
the upper confidence interval was 0.99. Earlier studies showed that cultural 
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factors are a stronger indication of diabetes outcomes(85) than SES but most 
current literature indicate that patients from lower SES have a much higher 
and disproportionate prevalence of diabetes(86-88).  Some studies suggest 
that measuring a combination of SES factors can be a more sensitive method 
to measure outcome disparities. In this study SES was directly measured by 
the proxy of mean zip code income for each observation in the dataset and it 
was also indirectly measured by controlling for type of payment used in the 
hospital; however the type of payment used was not a statistically significant 
variable for any of the results obtained.  
 
Regardless of accounting or not for SES, STEMI patients with comorbidities 
such as having a stroke or having history of a stroke, having diabetes, CKD, 
CHF, COPD and a diagnosis of depression made them less likely to receive 
diagnostic cardiac catheterizations. This may be partially explained by 
physical reasons; COPD or CHF patients may not be able to tolerate supine 
positions without undergoing general anesthesia and thus may be more likely 
to receive alternative reperfusion treatments and some patients with 
advanced chronic kidney disease may not tolerate the use of any contrast in 
diagnostic cardiac catheterization. 
 
The results of table 4-6 indicate that patients who were younger, obese, 
hyperlipidemic, smokers or having had history of being smokers were more 
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likely to receive diagnostic cardiac catheterizations. However these 
characteristics were not statistically significant for receiving PCI after 
undergoing cardiac catheterization. In contrast, smokers who were 
catheterized were more likely to receive CABG than non-smokers who did 
receive catheterization. This may be explained by the smoker‟s paradox. 
Studies have demonstrated that STEMI patients who smoke have better 
myocardial perfusion than non-smoker STEMI patients after undergoing 
myocardial reperfusion(89). The results obtained in this study suggest that 
smokers who were catheterized were more likely to receive CABG than PCI; 
this difference could be dependent on the number of vessel damage the 
STEMI smokers presented compared to non-smoker STEMI patients.  
 
After controlling for patient and hospital factors, those older than 85 years of 
age were less likely to receive diagnostic cardiac catheterization than 
younger patients. Nonetheless, from the 50% of patients over 85 years of 
age who did receive diagnostic cardiac catheterization, these were more 
likely to receive PCI than the younger cohorts who received diagnostic 
cardiac catheterization. Since 2004, the American Heart Association Practice 
Guidelines for STEMI patients have indicated primary PCI as first line of 
treatment for STEMI patients (Class I for those younger than 75 years of age 
and Class IIa in STEMI patients older than 75 years)(4, 68) , thus these 
results suggest that for the years 2006-2007 the guidelines were met for half 
of the patients over 85 years of age living in Florida at the time of their 
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STEMI. Nevertheless, patients 65-74 years old were 3.2 times more likely to 
undergo CABG than those older than 85. Although there may be medical 
and/or anatomical reasons for this outcome, the ACC/AHA Practice Guidelines 
have suggested that this may be due to surgeons coming under public 
scrutiny with regards to mortality rates(4).   
 
There was no statistically significant difference in the use of PCI between 
non-demented and demented patients who had already undergone diagnostic 
cardiac catheterization. Individuals from lower income areas or those with 
end stage renal disease seem to receive more PCI than their counterparts 
after initial diagnostic catheterization. A negative disparity in receiving PCI 
after initial catheterization was observed in patients with a diagnosis of 
diabetes, stroke, congestive heart failure and COPD after adjustment for 
patient and hospital factors.  
 
Female patients were 0.7 times less likely to receive diagnostic cardiac 
catheterization than males after controlling for potential confounders. Yet if 
they were catheterized, women were 40% more likely to receive PCI than 
men. Opposite results were reported by Hirakawa et al. (2006)(79); their 
study looked at the effect of emergency PCI on in hospital mortality in elderly  
patients with AMI and found that female patients received fewer PCIs. Just 
like Sloan et al.(78), Hirakawa et al.(79)  looked at all AMI instead of just 
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STEMI, therefore their results are less specific than those obtain in this 
study. 
 
Results from this study suggest that there was still a disparity by gender for 
more aggressive therapy; females were 0.5 times less likely than males to 
undergo CABG after receiving diagnostic catheterization and 0.5 times less 
likely to receive it within the first 24 hours after hospital admission than 
males.  
 
Demented STEMI patients who underwent diagnostic cardiac catheterization 
were less likely to receive CABG than those non-demented; however the 
effect disappeared when covariates were added to the model. CABG results 
from this study contrasted with those of Sloan et al. (2004) who found a 
statistically significant difference between demented and non demented 
patients even after adjustment. This may be attributable to several factors 
including the different potential confounding factors controlled for in both 
studies. The difference may also account to the fact that this study 
specifically evaluated STEMI patients while Sloan et al. evaluated acute 
myocardial infarctions (AMI) in general. 
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When evaluating the AHA guidelines for the timing of PCI, older patients 
were much less likely to receive same-day PCI or same-day CABG than 
younger patients. This result is consistent with that obtained from Pathak & 
Strom (2008)(66) for the years 2001-2005 in Florida. However, it is 
important to note that patients with prior CABG, females and the elderly 
have a higher risk of mortality if the CABG is performed early after the STEMI 
which may explain this disparity. The AAC/AHA Guidelines from 2004 indicate 
that STEMI patients have an elevated mortality from CABG if performed in 
the first 3 to 7 days after the MI(4). 
 
After adjusting for all variables of interest, socio-economic disparities were 
only statistically significant for those patients undergoing CABG.  A study by 
Bernheim et al. (2007) (67) showed a trend towards lower SES groups 
receiving fewer quality-of-care measures, however they did not report 
measures for CABG. 
 
A Cox regression analysis was performed to evaluate the length of hospital 
stay for STEMI patients with and without dementia. When patient factors 
were not added into the model, patients without dementia had significantly 
shorter length of hospital stay than patients with dementia. However when 
other factors were added into the model, this effect disappeared. Further 
analysis is needed to determine if there is an interaction effect of some 
comorbidities with dementia. 
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In order to clarify if the dementia definition used in this study was 
appropriate or if a stricter definition such Alzheimer‟s should have been used, 
a sensitivity analysis of the definition was conducted based on the main 
study model. The results obtained demonstrate that when exposure is limited 
to those with Alzheimer‟s the effect of dementia is slightly stronger than 
when the general definition is implemented. However, overall using the 
general definition did not statistically affect the outcome, in this case 
diagnostic cardiac catheterization. These results suggest that the disparity in 
outcomes for demented patients is dependent on the perception of medical 
personnel in the emergency department towards those with dementia. 
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5.2 Strengths and Limitations of the Study 
 
One of the main strengths of this study is that it is based on the 
comprehensive population coverage of Florida‟s hospital discharge database 
with little information bias. However it does bring in some uncontrollable 
limitations. First, the dataset includes only patients admitted to high volume 
PCI Florida hospitals with a STEMI diagnosis, therefore external validity is not 
applicable outside this strict definition.   
 
Underreporting of risk factors is also expected given the nature of the 
medical emergency under study (STEMI) and the coding procedures used, 
consequently some nondifferential misclassification may exist that may bias 
results toward the null. It is also impossible to determine how dementia was 
measured by the hospital staff. With this data temporality cannot be 
determined, whether the dementia code was written in the chart when the 
patient was admitted to the hospital affecting directly the outcome 
dependent on the exposure; or if dementia was coded later during the 
hospitalization after interviewing the patient or the family further, in this case 
not having affected the outcome directly.  
 
The underlying severity of the coronary condition of each of these patients 
cannot be measured directly and as a result this study does not adjust for it, 
nor does it account for previous cardiovascular procedures performed. Some 
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patients with multi-vessel disease or who had previous interventions may not 
have received PCI because it was not the optimal treatment while CABG was. 
On the other hand, patients with low left ventricular function, 
hemodinamically unstable or with high risk comorbidities may have had 
further indications to wait until stabilization to proceed with CABG. This 
limitation was not accounted for when days to procedure was measured. It is 
also important to mention that the variable „days to procedure‟ was only 
measured as a dichotomous variable, the procedure was either performed in 
the first 24 hours or it was not; the purpose was to capture the adherence to 
the ACC/AHA STEMI guidelines for PCI in STEMI patients. 
 
The use of average per capita income by zip code as proxy for socio-
economic status is an imperfect surrogate for individual level data. SES is an 
ecological variable therefore it only measures income per residential area; it 
is not a true estimate of the financial condition of the patients. Another 
frequently used SES measure is the method of hospital payment which was 
also adjusted for in this study; however this measure is also limited and does 
not provide significant information given that most of the elderly population 
has Medicare. 
 
When comorbidities were adjusted, the potential for over adjustment may be 
present. For example, depression is a prodromal symptom for dementia. 
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Obesity, hypertension, hyperlipidemia, depression and diabetes are all 
components of the metabolic syndrome, thus adjustment as a group may 
have yielded a different outcome.  
 
There may be some unmeasured residual confounding by the patient‟s age or 
hospital level that was not accounted for in this study. Even though age was 
a variable that was adjusted for in the study, it is well known that on average 
females outlive males, therefore some unmeasured effect may be left 
unaccounted for. 
 
Last but certainly not least, the data used does not contain specific codes for 
treatment refusal from the patients, their families or health care 
surrogates/proxies which may influence the results in this study. It is very 
common for very elderly patients in Florida to have “Do not resuscitate” 
(DNR) forms, which specify for CPR to be withheld or withdrawn in case of a 
myocardial infarction; they may have advanced directives, which specify 
their wishes upon a medical emergency; or they may have a living will in 
which they specify their healthcare wishes that may include to not receive 
therapy. By Florida law, patients with advanced dementia who do not have 
advanced directives or DNRs, their spouse or next-in- kin automatically 
acquire the legal authorized representative status and they may make the 
medical decisions for the demented patient.  
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Other studies known (41, 78, 79, 90) have measured the effect of dementia 
on the use of PCI as a secondary outcome.  A similar study to the one 
presented here was done by Sloan et al. in 2004; they measured the 
cardiovascular outcomes of Medicare beneficiaries but the population in that 
study included all kinds of Acute Myocardial Infarctions. This study uses a 
more specific approach in accordance with the ACC/AHA guidelines; PCI is 
specifically indicated for STEMI patients not non-STEMI. Thus despite all the 
mentioned limitations, this is the first known study to date that has directly 
measured the effect of dementia on the use of diagnostic cardiac 
catheterization among STEMI patients in Florida. 
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5.3 Future Research 
Further studies are needed to measure the impact of dementia on the quality 
of medical care received by dementia patients, especially in emergency 
settings. The need to include ways of measuring the legal aspect of the 
medical decisions for demented patients in epidemiological studies also 
requires further evaluation.  
 
A closer look at treatment disparities for demented ethnic minorities and 
women is urgently needed in order to adequately allocate resources and 
narrow the disparities. 
 
Evaluating other exposures within different groups by ethnicity, gender or 
medical condition in this cohort may better explain some of the results. For 
example knowing which women were previously exposed to hormone 
replacement therapy and who were not may enhance the results obtained by 
explaining the contrasting results for women undergoing catheterization and 
PCI versus CABG for both demented and non-demented female patients.  
 
Enhancing the analysis performed in this study by perhaps including hospital 
level effects and geographical patterns in the statistical analysis may be able 
to determine trends that can help decrease the gap in treatment disparities 
in Florida. An appraisal of medications and the temporality of the diagnostic 
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codes received by these patients may also help to better understand the 
results. 
 
Even though the AHA has helped improved the outcomes for STEMI patients 
in the last few years, it still does not have specific guidelines or algorithms 
for emergency personnel to follow when encountering elderly patients; 
therefore a national appraisal of disparities in treatment is urgently needed 
to not only narrow the gaps in treatment for elderly patients but those with 
dementia as well.  
 
5.4 Conclusion 
This study provides evidence that dementia is a limiting factor for receiving 
diagnostic cardiac catheterization after a STEMI. Results from this research 
coincide with many reported in the literature of outcomes research; women, 
the elderly and Black African American non-Hispanics are still subject to 
disparities, in this case diagnostic cardiac catheterization. 
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Appendix 1. Summary of recommendations from the American College of 
Cardiology and the American Heart Association for the management of 
STEMI, pg.e104 (4) 
 
Figure 7. Major components of time delay between onset of symptoms from ST-elevation MI and restoration 
of flow in the infarct artery. Plotted sequentially from left to right are shown the time for patients to recognize 
symptoms and seek medical attention, transportation to the hospital, in-hospital decision-making, and 
implementation of reperfusion strategy, in time for restoration of flow once the reperfusion strategy has been 
initiated. The time to initiate fibrinolytic therapy is the "door-to-needle" (D-N) time; this is followed by the 
period of time required for pharmacologic restoration of flow. More time is required to move the patient to the 
catheterization laboratory for a percutaneous coronary interventional (PCI) procedure, referred to as the 
"door-to-balloon" (D-B) time, but restoration of flow in the epicardial infarct artery occurs promptly after PCI. 
At the bottom are shown a variety of methods for speeding the time to reperfusion along with the goals for 
the time intervals for the various components of the time delay. Cath= catheterization; PCI = percutaneous 
coronary intervention; min = minutes; ECG = electrocardiogram; MI = myocardial infarction; Rx = therapy. 
*These bar graphs are meant to be semiquantitative and not to scale. Modified with permission from Cannon 
et al. J Thromb Thrombol 1994;1:27-34 (180). 
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Appendix 2. Applying Classification of Recommendations and Level of 
Evidence pg.e87(4). 
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Appendix 3. ICD-9 CM Coding Use for Comorbity 
HYPERTENSION: 
 401.0 is malignant essential HTN,  
 401.1 is benign essential HTN and  
 401.9 = essential HTN unspecified 
 403 = Hypertensive chronic kidney disease 
 403.0= Malignant 
 403.01= Malignant 
 403.10 = Benign 
 403.11 = Benign 
 403.9 =Unspecified 
 403.90 =Unspecified 
 403.91 =Unspecified 
DIABETES: 
 250 Diabetes mellitus 
 250.0 Diabetes mellitus without mention of complication [0-3] 
  Diabetes mellitus without mention of complication or 
manifestation classifiable to 250.1-250.9 
   Diabetes (mellitus) NOS 250.1  
   Diabetes with ketoacidosis [0-3]  
   Diabetic: acidosis without mention of coma  
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 ketosis without mention of coma 250.2 
Diabetes with hyperosmolarity [0-3] Hyperosmolar 
(nonketotic) coma 
 250.3 Diabetes with other coma [0-3] Diabetic coma (with 
ketoacidosis); Diabetic hypoglycemic coma Insulin coma 
NOS   
  250.4 Diabetes with renal manifestations [0-3]  
  250.5 Diabetes with ophthalmic manifestations [0-3] 
  250.6 Diabetes with neurological manifestations [0-3] 
  250.7 Diabetes with peripheral circulatory disorders [0-3] 
250.8 Diabetes with other specified manifestations [0-3] 
Diabetic hypoglycemia NOS; Hypoglycemic shock NOS   
 250.9 Diabetes with unspecified complication [0-3] 
STROKE: 
For Stroke codes: 
 430  Subarachnoid hemorrhage 
 431 Intracerebral hemorrhage 
 432.0 Nontraumatic extradural hemorrhage, Nontraumatic epidural 
hemorrhage 
 432.1 Subdural hemorrhage, Subdural hematoma, nontraumatic 
 432.9 Unspecified intracranial hemorrhage, Intracranial hemorrhage 
NOS 
 433.0, 433.01 Basilar artery 
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 433.1, 433.10 Carotid artery  
 433.2, 433.20 Vertebral artery  
 433.3, 433.30 Multiple and bilateral  
 433.8, 433.81 Other specified precerebral artery 
 433.9, 433.91 Unspecified precerebral artery, Precerebral artery NOS 
 434.00, 434.01 thrombotic 
 434.10, 434.11 Cerebral embolism 
 434.91 is general or stroke in evolution, cerebrovascular accident 
 435.0 Basilar artery syndrome  
  435.1 Vertebral artery syndrome 
  435.2 Subclavian steal syndrome 
  435.3 Vertebrobasilar artery syndrome 
  435.8 Other specified transient cerebral ischemias 
  435.9 Unspecified transient cerebral ischemia, progressive  
 436.0 apoplectic 
 997.02 Iatrogenic cerebrovascular infarction or hemorrhage 
Postoperative stroke 
 V12.54 Transient ischemic attack (TIA), and cerebral infarction without 
residual deficits 
 
 HYPERLIPIDEMIA: 
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  272.2 Hyperlipidemia is defined as high lipids, hypercholesterolemia 
and hypercholesterolemia with hyperglycemia endogenous: 272 
272.0, 272.1, 272.2, 272.3, 272.4 
 
OBESITY: 
  278.00 represents obesity and overweight 
 
 SMOKER: 
 305.1 for tabacco use disorder and V15.82 for hx of tabacco use 
 
 ALCOHOL ABUSE: 
303.9, 303, 303.00, 303.01, 303.02, 303.03, 303.9, 303.90, 303.91 
303.92, 303.93 which stands for Chronic alcoholism/Dipsomania  
 V11.3, V79.1, V11.3 for alcoholism 
 
 DEPRESSION: 
 V79 
 300.4 Dysthymic disorder  
 311 depression NOS 
 Major depresive disorder/recurrent episode: 296.2, 296.20, 
296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.3, 
296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36 
 Bipolar I disorder, most recent episode (or current) depressed 
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 296.5, 296.50, 296.5, 296.52, 296.53, 296.54, 296.55, 
296.56 
 
Chronic Kidney Disease (CKD): 
 403 Hypertensive chronic kidney disease [0-1] 
 403.0 Malignant  
 403.1 Benign 
 403.9 Unspecified 
 585 Chronic kidney disease (CKD): 
 585.1 Chronic kidney disease, Stage I 
 585.2 Chronic kidney disease, Stage II (mild) 
 585.3 Chronic kidney disease, Stage III (moderate) 
 585.4 Chronic kidney disease, Stage IV (severe) 
 585.5 Chronic kidney disease, Stage V  
 585.9 Chronic kidney disease, unspecified 
 
 End Stage Renal Disease (ESRD): 
585.6 End stage renal disease Chronic kidney disease, stage V 
requiring chronic dialysis 
 
 Congestive Heart Failure (CHF): 
 402.0, 402.00, 402.01, 402.1, 402.11, 402.9, 402.90, 402.91  
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Hypertensive Heart Disease 
 404 Hypertensive heart and chronic kidney disease [0-3] 
 404.0 Malignant  
 404.1 Benign 
 404.9 Unspecified 
 428.0 Congestive heart failure, unspecified 
428.1 Left heart failure (Acute edema of lung with heart disease 
NOS or heart failure, Acute pulmonary edema with heart 
disease NOS or heart failure Cardiac asthma, Left 
ventricular failure) 
428.9 Heart failure, unspecified Cardiac failure NOS, Heart 
failure NOS, Myocardial failure NOS, Weak heart 
 
 COPD: Chronic Obstructive Pulmonary Disease: 
 490 Bronchitis not specified as acute or chronic 
 491 Chronic Bronchitis 
 491.0, 491.1, 491.2 Obstructive chronic bronchitis 
 491.20 Without exacerbation / Emphysema with chronic 
bronchitis 
 491.21 With (acute) exacerbation / Acute 
exacerbation of chronic obstructive pulmonary 
disease [COPD], Decompensated chronic 
obstructive pulmonary disease [COPD], 
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Decompensated chronic obstructive pulmonary 
disease [COPD] with exacerbation 
  491.22 With acute bronchitis 
 492 Emphysema 
  492.0 492.8 
 493 Asthma 
  493.0 493.00 493.01 493.02 
  493.1 493.10 493.11 493.12 
  493.2 493.20 493.21 493.22 
  493.9 493.90 493.91 493.12 
 494 Bronchiectasis 
  494.0 494.1 
 495 Extrinsic Allergic alveolitis  
495.0 495.1 495.2 495.3 495.4 495.5 495.6 495.7 
495.8 495.9 
496 Chronic Airway Obstruction, not elsewhere 
classified 
 
 
 
 
 
